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Welcome Note 
On behalf of the Center of Pharmaceutical Engineering of Technische Universität Braunschweig 
and the Scientific Committee it is my great pleasure to welcome you to the 3rd International 
Symposium on Pharmaceutical Engineering Research – SPhERe. The conference is held from 
September 25 – 27, 2019 in Braunschweig, Germany. 
The Center of Pharmaceutical Engineering (PVZ) has been established in 2017 as an 
interdisciplinary research center at the Technische Universität Braunschweig offering excellent 
working and research conditions for approx. 100 scientists from pharmacy, process engineering, 
and microtechnology. Altogether scientists of over 20 different research groups of TU 
Braunschweig, Leibniz University of Hannover and TU Clausthal conduct joint research 
programmes at PVZ.  
Working together in mixed, interdisciplinary teams under a common roof provides a unique 
environment to develop, test and apply new methods and technologies for pharmaceutical 
production. These beneficial surroundings emphasize our vision on cost-efficient production of 
medicinal products and customized drug supply.  
SPhERe 2019 is our third conference on Pharmaceutical Engineering Research. SPhERe 
addresses major topics of innovative production methods and processes to develop low-cost, 
effective and customized drugs. Bringing together pharmacists, process engineers, production 
engineers as well as microtechnologists from academia and industry facilitates discussions and 
the exchange of ideas between representatives of different research disciplines and strengthens 
the community of pharmaceutical engineering.  
The symposium features renowned speakers who share, discuss, and dissect significant new 
developments and scientific advancements with relevance to the future of pharmaceutical 
engineering and related fields. 
Our first-time Hot Topic Session highlights different aspects of cannabis production for medicinal 
use. This special session focuses on the current debate and addresses the challenges on the 
way to safe and effective cannabis products that best serve patients' health and meet the legal 
requirements. 
We very much welcome you to Braunschweig, the Lion City! Enjoy SPhERe 2019 and your stay. 
Prof. Dr.-Ing. Stephan Scholl 
Conference Chair SPhERe 2019 
https://doi.org/10.24355/dbbs.084-202001220921-0
Notes on Content of SPhERe Conference Proceedings 
Conference abstracts authorised for Open Access publication are listed 
alphabetically according to the surname of the presenting author. 
The name of the presenting author is underlined in each 
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INFLUENCE OF GLYCEROL ON THE POLYMORPHIC BEHAVIOR OF SOLID 
TRIGLYCERIDE NANOPARTICLES STABILIZED WITH POLY(VINYL ALCOHOL) 
N. Bauer1,2, H.Bunjes1,2 
1TU Braunschweig; Institut für Pharmazeutische Technologie; Mendelssohnstraße 1, 38106 Braunschweig; 
2PVZ - Zentrum für Pharmaverfahrenstechnik; Franz-Liszt-Straße 35A, 38106 Braunschweig; 
n.bauer@tu-braunschweig.de; heike.bunjes@tu-braunschweig.de
ABSTRACT 
Colloidal dispersions of lipids, e.g. triglycerides, are under intensive investigation as drug delivery systems. Solid 
triglyceride nanoparticles exist in different polymorphic modifications. The aim of this study was to investigate the effects 
of the addition of glycerol, which can be used for the isotonization of such dispersions, on the polymorphic behavior of 
poly(vinyl alcohol)-stabilized tripalmitin nanoparticles. Glycerol was added to the nanoparticle dispersions at different 
concentrations in the heat.  
The dispersions were investigated for their thermal behavior and storage stability with regard to particle size and 
polymorphic transitions of the triglyceride matrix, using photon correlation spectroscopy, differential scanning 
calorimetry and X-ray diffraction. The addition of glycerol led to a decreasing crystallization temperature of the 
nanoparticles and slowed down the polymorphic transition into the stable β-modification. 
Keywords: Triglyceride nanodispersions, crystallization, polymorphism. 
INTRODUCTION 
Lipid nanoparticles are under intensive investigation as 
drug delivery systems for poorly-water soluble drugs 
[Bunjes, 2010]. Many of the lipids used for the 
preparation, for example triglycerides, are polymorphic 
substances. Triglycerides occur in three different crystal 
modifications: the metastable α- and β’-modification 
and the stable β-modification. These modifications 
differ from each other in their physicochemical 
properties, which might have an influence on the drug 
loading capacity [Westesen, 1997]. 
After crystallization, triglyceride nanoparticles undergo 
polymorphic transitions from the metastable α- into the 
stable β-modification, sometimes via the β’-
modification. These transitions are monotropic and 
depend on several factors, like matrix composition as 
well as the type of emulsifier used, additives or storage 
conditions.  
The aim of this study was to investigate the influence of 
the additive glycerol, which is often used for 
isotonization of triglyceride nanodispersions, on the 
polymorphic behavior of the lipid nanoparticles. 
RESEARCH CONCEPT 
A dispersion consisting of 10 % tripalmitin (Dynasan 
116®, Condea), 10 % PVA (Mowiol® 3-83, Clariant), 
and bidestilled water in which PVA was dissolved (all 
concentrations w/w) was prepared by melt 
homogenization. First, the lipid and the aqueous phase 
were heated at ~80 °C separately. Both phases were 
combined and prehomogenized with an ultra-turrax 
(IKA T25 digital Ultra-Turrax; S25N-10G, Ika-Werke) 
at 13.000 rpm for 4 min. The predispersion was 
homogenized in a Microfluidizer M110S instrument 
(Microfluidics) for 10 cycles at 800 bar and ~80 °C. The 
hot dispersion was divided into 10 ml fractions which 
were allowed to cool to 40 °C. In order to set the 
glycerol content, the fractions were combined with 
10 ml of a glycerol-containing solution and incubated at 
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40 °C for 30 min. The dispersions were cooled to 5 °C 
for 30 min to crystallize the nanoparticles and 
subsequently stored at 20 °C. The final dispersions 
contained 5 % triglyceride, 5 % PVA and 0 %, 1 %, 
2 %, 5 %, 10 %, 15 % and 20 % glycerol, respectively. 
Particle size was measured by photon correlation 
spectroscopy (PCS) with a Zetasizer Nano ZS 
instrument (Malvern) at 25 °C and an angle of 173 °. 
The dispersions were diluted with purified and particle-
free water. The z-average diameter and PDI were given 
as mean of three measurements of 5 min each after 
5 min of equilibration.  
Differential scanning calorimetry (DSC) measurements 
were performed in a DSC 1 Stare System with a full 
range sensor (FRS 5) and a sample robot (Mettler 
Toledo GmbH). About 15 µl of the dispersions were 
accurately weighed into aluminum crucibles that were 
cold sealed. The samples were heated to 85 °C with a 
heating rate of 10 °C/min, held at that temperature for 
5 min, cooled to -5 °C (10 °C/min) and heated again to 
85 °C (10 °C/min). All measurements were performed 
against an empty reference crucible and under nitrogen 
purge. The enthalpies observed were normalized for the 
weight of the samples. 
The melting enthalpies were used to approximate the 
fraction of particles in the different polymorphic forms. 
To determine the fraction of particles in the stable β-
modification, the enthalpy values of the β-form melting 
transition were calculated according to [Joseph, 2015]. 
A small amount of the dispersions was tempered at 
37 °C for 96 h to obtain a β-reference dispersion. The 
complete transition of this sample into the β-polymorph 
was confirmed with X-ray diffraction. 
X-ray measurements were performed with a small- and
wide-angle X-ray diffraction setup (SAXSess, Anton
Paar), equipped with a copper anode (λ = 1.54 nm). The
sample was measured in a quartz capillary sample holder
in 25 runs of 30 s each at 20 °C.
RESULTS 
All dispersions had a milky white appearance with a z-
average diameter of about 80 nm and a narrow particle 
size distribution with PDI values between 0.10 and 0.12. 
DSC investigations revealed that all nanoparticles were 
in the metastable α-polymorph directly after 
preparation. Almost no differences were observed for 
the different samples during the first heating step. X-ray 
Fig. 1: Onset of crystallization events for dispersions 
with increasing glycerol concentration. 
Fig. 2: Fraction of nanoparticles in the β-modification 
after storage at 20 °C as determined by DSC. 
diffraction patterns confirmed that all particles were 
present in the metastable α-polymorph with only 
marginal differences in the diffractograms for samples 
with different glycerol content. During cooling in the 
DSC, the samples displayed a linearly decreasing 
crystallization temperature with increasing glycerol 
content (Fig. 1).  
Over a storage time of about 7 months at 20 °C, the 
transition of nanoparticles into the stable β-modification 
distinctly slowed down with increasing glycerol content 
(Fig. 2). After storage, the fraction of particles in the 
stable β-modification varied from 25 % (0 % glycerol) 
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DISCUSSION 
The use of PVA as emulsifier in solid triglyceride 
nanoparticles led to the formation of the α-modification 
with a remarkable stability in agreement with previous 
studies with tristearin nanodispersions [Rosenblatt, 
2008; Joseph, 2015]. The addition of glycerol after 
homogenization did not change the particle size of the 
dispersions noticeably but influenced the crystallization 
temperature as well as the polymorphic behavior of the 
lipid nanoparticles.  
The decrease in crystallization temperature may indicate 
a change of the composition of the nanoparticles as it is, 
for example, obsorved upon drug loading of triglyceride 
nanoparticles [Roese, 2017]. As the polarity of glycerol 
is very high it is unlikely that it interacts with the matrix 
lipid itself. Instead, it may modify the interaction 
between PVA and the lipid. The assumed increase in 
interaction could be an explanation for the higher 
stability of the metastable α-polymorph in samples 
containing a high concentration of glycerol. 
CONCLUSIONS 
In dispersions of PVA-stabilized tripalmitin 
nanoparticles, the addition of glycerol leads to a 
decrease in crystallization temperature and slows down 
the polymorphic transition into the stable β-
modification. It is unlikely that glycerol molecules are 
distributed into the particles due to their high polarity. A 
possible cause for the observed phenomena could be a 
specific interaction between glycerol and PVA which 
affects the composition of the nanoparticles. However, 
the exact mechanism is still unclear and remains to be 
elucidated. 
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SELF-IMMOBILIZING BIOCATALYSTS FOR FLUIDIC REACTION CASCADES 
Patrick Bitterwolf1, Theo Peschke1, Manfred Maier1, Sabrina Gallus1, Teresa Burgahn1, Esther Mittmann1, Martin 
Peng1, Kersten S. Rabe1, Christof M. Niemeyer1  
1Institute for Biological Interfaces (IBG 1), Karlsruhe Institute of Technology, Karlsruhe, Germany 
ABSTRACT 
The industrial implementation of whole-cells and enzymes in flow biocatalysis microreactors is essential for the 
emergence of a biobased circular economy. Major challenges concern the efficient immobilization of delicate enzymes 
inside miniaturized reactors without compromising their catalytic activity. We describe the design and application of four 
different immobilization techniques including self-immobilizing whole-cells and purified enzymes on magnetic 
microbeads, as well as reactor modules manufactured by 3D printing of bioinks containing thermostable enzymes. To 
increase the volumetric activity of our microreactors we furthermore developed and applied self-assembling all-enzyme 
hydrogels with cofactor-regenerating capabilities. The resulting reactor formats have excellent operational stability times 
of > 14 days and maximum space-time yields of > 450 g product/L-1day-1 paving the way for mild and effective 
immobilization techniques of biocatalysts in microfluidic systems. 
Keywords: self-immobilizing, enzymes, continuous flow biocatalysis, cascade reactions, stereoselective 
INTRODUCTION 
Biocatalysis is currently being transformed by the use of 
biomimetic fluidic approaches enabling 
compartmentalized multiple enzyme cascades  for the 
sustainable and continuous production of fine- and 
value-added chemicals in the industrial “white” 
biotechnology sector.[1, 2] Apart from optimizing the 
biocatalysts by protein engineering, effective 
immobilization techniques are essential to enable 
precise temporal and spatial reaction control in fluidic 
microreactors. Thus for the establishment of artificial 
fluidic cascades new approaches for the immobilization 
of accessible and active biocatalysts are needed. 
RESEARCH CONCEPT 
In order to retain the active biocatalysts under 
continuous flow conditions, we developed different 
“self-immobilizing” biocatalysts including from whole-
cells[3] or pure enzymes[4] in combination with 
superparamagnetic microparticles as well as reactor 
modules manufactured by 3D printing of bioinks 
containing thermostable enzymes.[5] To further increase 
the volumetric activity of our microreactors, we 
developed self-assembling and cofactor-regenerating 
all-enzyme hydrogels, consisting of either an (R)- or an 
(S)-enantiospecific ketoreductase and the nicotinamide 
adenine dinucleotide phosphate regenerating glucose 1-
dehydrogenase.[6, 7] 
RESULTS & DISCUSSION 
For the design of “self-immobilizing” whole-cells we 
generated bacterial strains that can selectively bind to 
solid substrates containing an appropriate binding tag,. 
In an initial work, we employed the cell-surface display 
of the strepatividin-binding peptide (SBP), the 
SpyTag/SpyCatcher (ST/SC) system or a HaloTag 
variant based on the outer membrane protein Lpp-ompA 
, which led to a spontaneous covalent coupling of 
magnetic microbeads carrying streptavidin (STV), a 
ST/SC component or a chlorohexyl (CH) -moiety.[3] At 
the same time functional content could be expressed in 
the cytosol of the immobilized cells, as we demonstrated 
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employing fluorescent proteins or stereoselective 
ketoreductase enzymes. The latter strains gave high 
selectivities for specific immobilization onto 
complementary surfaces and also in the whole-cell 
stereospecific transformation of a prochiral CS-
symmetric nitrodiketone.  
Implementing enzyme cascades into future 
biocatalytic processes enables the use of 
compartmentalized microfluidic reactors. However, a 
major challenge in the establishment of microfluidic 
enzyme cascades concerns the immobilization of 
isolated enzymes. To this end we developed “self-
immobilizing” enzyme biocatalysts based on (R)- and 
(S)-selective ketoreductases in combination with an 
NADPH regenerating glucose-1-dehydrogenase 
anchored on magnetic microbeads.[4] The enzymes were 
tagged with SBP, ST or halo-based oligonucleotide 
binder (HOB), respectively, and bound to the 
corresponding streptavidin (STV), SC or chlorohexyl 
(CH) coated microbeads. The enzyme-modified beads 
were loaded in four-channel microfluidic chips to create 
compartments that have the capability for either (R)- or 
(S)-selective reduction of the prochiral CS-symmetrical 
substrate 5-nitrononane-2,8-dione (NDK). Analysis of 
the isomeric hydroxyketone and diol products by chiral 
HPLC was used to quantitatively characterize the 
performance of reactors configured with different 
amounts of the enzymes. Long operating times of up to 
14 days indicated stable enzyme immobilization and the 
general robustness of the reactor. Even more important, 
by fine-tuning of compartment size and loading, the 
overall product distribution could be controlled to 
selectively produce a single meso diol with nearly 
quantitative conversion (>95%) and excellent 
stereoselectivity (d.r. > 99:1) in a continuous flow 
process.  
In a parallel approach we demonstrate the 
utility of thermostable enzymes in the generation of 
biocatalytic agarose-based inks for a simple 
temperature-controlled 3D printing process.[5] As 
examples we utilized an esterase and an alcohol 
dehydrogenase from thermophilic organisms as well as 
a decarboxylase that was thermostabilized by directed 
protein evolution. We used the resulting 3D-printed 
parts for a continuous, two-step sequential 
biotransformation in a fluidic setup. 
To further increase the volumetric activity of 
such reactors, we have recently developed self-
assembling all-enzyme hydrogels with cofactor-
regenerating capabilities, consisting 100% of either an 
(R)- or an (S)-enantiospecific ketoreductase combined 
with the NADPH-regenerating glucose 1-
dehydrogenase.[6] Mounted in microfluidic reactors, the 
gels show excellent stereoselectivity (> 99% ee.) with 
near quantitative conversion (> 90%) in the reduction of 
different prochiral ketones along with high robustness 
under process and storage conditions. The gels 
constitute a compartment in which reaction 
intermediates are retained, thereby enabling 
extraordinary high total turnover numbers of the 
expensive cofactor NADP(H). Coupling of such reactor 
modules allows to facilitate multi step reaction cascades. 
CONCLUSIONS 
The field of biocatalysis demands practical and effective 
methods for the immobilization of the corresponding 
biocatalysts. We developed four different approaches 
including whole-cells, purified enzymes as well as 
enzymes bound or entrapped into carrier materials like 
magnetic microbeads or agarose, respectively. 
 Maximizing space–time yields (STY) of 
biocatalytic flow processes is essential for the 
establishment of a circular biobased economy. We 
present a comparative study in which different 
biocatalytic flow reactor concepts were tested with the 
same enzyme, the (R)-selective alcohol dehydrogenase 
from Lactobacillus brevis (LbADH).[7] To enable cross-
platform comparison, STY values were determined for 
the various reactor modules. While mono- and 
multilayer coatings of the reactor surface led to STY < 
10, higher productivity was achieved with packed-bed 
reactors (STY ≈ 100) and the densely packed hydrogels 
(STY > 450). The latter modules could be operated for 
prolonged times (>6 days). Given that our approach is 
not limited to specific enzymes, we anticipate that 
compartmentalized microfluidic reaction modules 
equipped with self-immobilizing biocatalysts would be 
of great utility for numerous biocatalytic and even 
chemo-enzymatic cascade reactions under continuous 
flow conditions. 
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ELECTROSPINNING, PHOTOCROSSLINKING OF ARYLAZIDE CHITOSAN NANOFIBERS 
AND APPLICATION AS BIOCATALYST SUPPORT MATRIX 
Henrik-Alexander Christ*, Henning Menzel*. 
*Technische Universität Braunschweig, Institut für Technische Chemie, Hagenring 30, 38106 Braunschweig,
Deutschland, h.christ@tu-braunschweig.de 
ABSTRACT 
A process yielding water stable chitosan nanofiber mats is described and their significance in the field of biocatalyst 
immobilization is proven. Electrospinning was adapted to produce nanofibers from chitosan derivatives bearing 
photoreactive arylazide groups. These photoreactive groups of chitosan were then crosslinked by irradiation with 
UV-light. This stabilizes the fiber morphology even upon incubation in water and provides an alternative to crosslinking 
with harmful chemicals. Applicability of the fiber mats as enzyme immobilization matrix was demonstrated, using 
β-D-galactosidase as model enzyme. Although an initial leaching of enzyme was observed, after 40 days of incubation a 
significant portion of active enzyme is still present on the fibers. Thus, the fiber mats are suitable matrices to support 
enzymes and can revolutionize future enzymatic production processes of e.g. active pharmaceutical ingredients. 
Keywords: arylazide chitosan, electrospun nanofibers, photochemical crosslinking, enzyme immobilization. 
INTRODUCTION 
To this day, applications of enzymes in the production 
of active pharmaceutical ingredients (API) are limited 
by losses in enzyme activity or difficulties in reusability 
and handling. Enzyme immobilization onto a structural 
and porous support may help to overcome these 
obstacles (Sheldon, 2007). Chitosan nanofibers are 
promising candidates as immobilization matrices for 
biocatalysts because of their high surface-to-volume 
ratio in combination with an ease of handling. This may 
lead to the development of a new class of biocatalyst-
supports (Misson et al., 2015). As chitosan is still one of 
the most promising polysaccharides derived from 
nature, its electrospinning process has been studied 
intensively for the last two decades (Ding et al., 2014). 
An important improvement came from (Zhang et al., 
2008) by blending of chitosan with poly(ethylene oxide) 
(PEO) of a very high molecular weight. This enabled 
production of nanofibers. However, most of the 
previously spun nanofibers tend to lose structure 
completely upon contact with water. Chemical 
modification of chitosan with photo-reactive 
crosslinking groups before electrospinning can help to 
solve this problem (Hadler et al., 2017). In this way an 
UV-light induced crosslinking is possible and a very 
good alternative to common crosslinking agents such as 
Genipin or Glutaraldehyde. The crosslinked 
hydrophilic, but water stable nanofibers could be used 
for immobilization of enzymatic catalysts to improve 
production processes for various API’s. 
RESEARCH CONCEPT 
All chemicals were obtained from Sigma Aldrich unless 
otherwise stated. Poly(ethylene oxide) (PEO, 
Mv = 5.000 kDa) was used as obtained. Chitosan (CsH, 
Mw = 190 – 310 kDa, 15 – 25 % degree of acetylation) 
was purified, using a method of (Gan and Wang, 2007). 
Arylazide chitosan (CsH-Az) was synthesized by 
4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholi
nium chloride (DMT-MM) mediated aqueous amide 
coupling of sodium-4-azidobenzoate and amine 
functions of chitosan by a method of (Hadler et al., 
2017). Spinning solutions were prepared using blends of 
CsH-Az and PEO in a solvent system consisting of 3 % 
acetic acid in deionized water and methanol (10:1 v/v) 
as a co-solvent. The blends had a PEO content of 
5 % (w/w) and were prepared with an overall polymer 
concentration of 4 % (w/v). All fibers were spun on a 
custom-made electrospinning device (see Figure 1) by 
extruding spinning solution through a flat cannula (I, 
B/BRAUN, inner diameter = 0.2 mm) to a plastic syringe 
(II, B/BRAUN, 5 mL). A syringe pump (III, HLL 
LANDGRAF LABORSYSTEME, LA 30) was used to 
maintain a constant flow rate. A fiber-forming jet was 
achieved by applying a high electric potential 
(IV, HEINZIGER, LNC-30000-2 pos high voltage 
generator) between the spinneret and the collector. All 
fibers were collected on a rotating spherical alumina 
cylinder (V, IKA LABORTECHNIK, RW20 DZM stirrer, 
1000 rpm) with a height of 5 cm and a radius of 3 cm. 
The collector was covered in a strip of plastic mesh 
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(WINDHAGER, Fiberglas Anthrazit (fly-screen) which 
improved the handling of the fibers. The distance 
between spinneret and collector, the electrical potential 
and the flow rate of spinning solution were varied in 
order to achieve a stable production process. Produced 
fibers were analyzed by IR-spectroscopy and SEM 
images. 
Figure 1: Schematic setup of custom-made 
electrospinning device (I = cannula, II = plastic syringe, 
III = syringe pump, IV = high voltage generator, 
V = collector). 
Samples of the fiber meshes were photo-crosslinked by 
subjecting them to light of a mercury vapor UV-lamp 
(ORIEL, 100 mW/cm2) for a given time. The lamp was 
equipped with a water IR-filter and a glass UV-filter 
(νmax = 330 ± 70 nm). Completion of crosslinking was 
evaluated by recording IR-spectra of samples. Water 
stability tests were carried out by incubation of samples 
in deionized water for a given time and subsequent 
drying with a N2-stream. Scanning electron microscopy 
(SEM) images were used to evaluate water stability of 
fibers. Samples with 100 mm2 of photocrosslinked fiber 
mesh were used for immobilization of 
β-D-galactosidase (β-Gal) from A. oryzae as model 
enzyme via ionic interaction. Three samples per 
experiment were washed with citrate-phosphate-buffer 
(CP) at pH = 4.5 for 24 h, subsequently incubated with 
0.506 units of β-D-galactosidase in CP at r.t. for 24 h 
and stored in Millipore water in fridge until further use. 
Remaining activity of immobilized enzymes was 
determined via O-Nitrophenyl-β-D-galactopyranoside 
(ONPG) at 0, 20 and 40 d. This was done by incubation 
of samples in ONPG (5 mM, 1 mL, 30 °C, 700 rpm 
inversion) and subsequent stopping of reaction after 
10 min with borate buffer. UV-VIS-spectroscopy at 
420 nm was used to determine the amount of cleaved 
ONPG and calculate the remaining activity of 
immobilized β-Gal relative to initial activity in 
immobilization solution before contact with samples. 
RESULTS AND DISCUSSION 
By reproducing electrospinning experiments from 
(Zhang et al., 2008) with our custom-made 
electrospining setup, we could obtain chitosan (CsH) 
nanofibers, that showed poor stability in water 
incubation tests. A complete loss of nanofiber 
morphology was observed after contact with water. This 
phenomenon has been described before and highlights 
the need of a crosslinking method to increase the water 
stability of the fibers. Previous approaches consist of a 
treatment of fibers with a crosslinking agent such as 
Genipin (Li et al., 2015), Glutaraldehyde (Schiffman 
and Schauer, 2007) or Tripolyphosphate (Sarkar et al., 
2013). All of these methods have the drawback that 
fibers have to be treated with a chemical and can 
potentially be damaged during this process. A more 
elegant method is crosslinking of chitosan fibers by 
irradiation with UV-light. In order to enhance CsH with 
photocrosslinking functionalities, arylazide groups were 
introduced by a DMT-MM mediated aqueous amide 
coupling of sodium 4-azidobenzoate and amine 
functions of CsH. The resulting structure of chitosan-
azide (CsH-Az) is shown in Figure 2. For this study we 
produced CsH-Az with a degree of modification (DM) 
in a range of 1 – 10 %.  DM is defined as the fraction of 
modified repetition units over the sum of all repetition 
units in CsH (see Figure 2). 
Figure 2: Schematic structure of CsH-Az: 
(m = acetylated glucosamine, n = glucosamine, 
o = arylazide modified repetition unit).
Modification of glucosamine repetition units with 
arylazide groups changes the properties of chitosan in a 
spinning solution drastically. Therefore, established 
parameters of the spinning process have to be adapted. 
Significant improvements of the spinning process and 
resulting fibers were achieved by substitution of DMSO 
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with Methanol (MeOH) as a co-solvent. This led to a 
decrease of viscosity of the spinning solution and by 
this, to a much more stable spinning process. We were 
able spin solutions of CsH-Az/PEO-blends (w/w = 95/5, 
DM = 0 % / 1.9 % / 3.8 % / 9.0 %) using the improved 
AcOH/MeOH-solvent system in a stable process 
(spinning time over 3 h, rotating drum collector at 
1000 rpm, voltage of 14 kV, cannula-collector-distance 
of 25 cm, solution flow rate of 1 mL/h). Best results 
were achieved for the CsH-Az-6/PEO-blend (DM of 
3.8 %). The resulting fibers, in contrast to other 
CsH-Az/PEO-blends, had nearly no bead-like defects 
and were well oriented in a mostly parallel and straight 
manner. The average diameter was 640 +/- 290 nm. A 
SEM image of this morphology is shown in Figure 4. 
Fibers of CsH-Az/PEO-blends with a DM of 1.9 % or 
9.0 % respectively had bead-like defects and the 
complementary spinning process was less stable than for 
a DM of 3.8 % (CsH-Az-6). This clearly indicates that a 
change in DM of CsH-Az requires an adaption of the 
specific process conditions as it changes the behavior of 
the polymer chains in the spinning solution. After 
spinning, CsH-Az/PEO-fibers can be crosslinked via 
irradiation with UV-light. This was done with a 
Hg-vapor UV-lamp at a light intensity of 100 mW/cm2. 
We were able to crosslink samples within a time 
spectrum of 30 – 180 s as established by ATR-IR-
spectra, SEM-images and water stability tests. 
Figure 3: Decreasing intensity of azide signal 
(magnified section) in ATR-IR-spectra of CsH-Az/PEO 
fiber meshes at varying UV-light exposure times during 
photo-crosslinking process. 
ATR-IR-spectra of fiber samples before and after 
irradiation show decrease of a signal at 2130 cm-1 (see 
Figure 3). This signal corresponds to azide groups of 
CsH-Az. Further evidence for a successful crosslinking 
process was provided by incubation experiments in 
water. CsH as well as CsH-Az is hydrophilic and can be 
dissolved in slightly acidic water conditions (pH 4-5). 
However, crosslinked chitosan forms a hydrogel in 
water. The crosslinked CsH-Az/PEO fibers behave 
similarly: Samples examined at macroscopic level 
during and after incubation showed complete water 
stability for over 24 h. The dry white fiber mesh 
becomes semi-transparent during incubation and 
reverses back during drying. Examination of the 
incubation process by light microscopy reveals a 
significant increase in fiber diameter during incubation. 
SEM-images of the fiber meshes after subsequent drying 
showed partial fusing of fibers but retention of general 
fiber mesh structure. A typical morphology of such 
partially fused fibers is shown in Figure 4. 
Figure 4: SEM image of fibers from 
CsH-Az-6/PEO-blend spun from AcOH/MeOH solvent 
system before (A) and after (B) crosslinking and 
incubation in deionized water. 
Incubated fiber samples (Figure 4) appear, compared to 
non-incubated fibers, washed-out and fused together. A 
lot of pores have formed in between fusing fibers. Some 
fibers seem to stick together and form fiber bundles. 
This morphology did not change with irradiation time or 
incubation time. It seems that morphology changes 
happen during first contact with an incubation solution. 
To demonstrate a potential application of CsH-Az 
nanofibers, β-Gal was immobilized via ionic interaction 
and adsorption on fiber surfaces as proof of concept. As 
analysis of exact enzyme loading on fibers is not trivial, 
relative activity standardized with activity of free 
enzyme in CP buffer at pH = 4.5 was used. Initially 
directly after incubation, we found a high relative 
activity of 75 % in case of CsH-Az-6 and 80 % for 
CsH-Az-9 (Figure 5). 
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Figure 5: Remaining relative catalytic ability of β-Gal 
immobilized on photocrosslinked nanofiber samples 
after 0, 20 and 40 d of incubation in Millipore water. 
Relative immobilized enzyme activity was reduced to 
under 30 % after storage of 20 to 40 days. These results 
suggest a good initial loading capacity of CsH-Az 
nanofibers but also a significant loss of activity over 
time. This could be attributed to leaching of enzymes or 
loss of active structure. Nevertheless, it can be 
concluded that at least 22 % of active enzymes were 
present on CsH-Az nanofibers after 40 days. 
CONCLUSIONS 
Adapting an electrospinning process for chitosan 
derivatives bearing photoreactive arylazide groups was 
accomplished using Methanol as co-solvent. 
Photoreactive arylazide groups from CsH-Az were used 
to induce crosslinking of polymer networks via 
irradiation with UV-light. Fully crosslinked fibers were 
shown to form a hydrogel-like structure when incubated 
in water or acidic buffer systems but retain fibrous 
morphology. Applicability as promising enzyme 
immobilization matrix was proven with 
β-D-galactosidase as model enzyme. After initial 
leaching during the first days, remaining catalytic 
abilities of immobilized enzymes could be retained over 
40 days of incubation. These findings only hint the full 
potential of nanofibers from photoreactive chitosan, 
which is still subject of our ongoing research. 
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ABSTRACT 
Premix membrane emulsification is a promising method to produce colloidal lipid carrier systems, e.g. triglyceride 
nanoemulsions, with small particle sizes and narrow particle size distributions for intravenous administration. The 
stability of these systems can be affected by Ostwald ripening. The process of Ostwald ripening in emulsions of 
medium chain triglycerides stabilized with sucrose laurate was monitored by particle size measurements with photon 
correlation spectroscopy. Two different preparation methods were used and the concentration of free emulsifier 
measured to learn more about the influencing parameters.  
The concentration of free sucrose laurate turned out to be the main influencing parameter and should be about zero to 
minimize Ostwald ripening in the emulsions. 
Keywords: Premix membrane emulsification, Ostwald ripening, triglyceride emulsion 
INTRODUCTION 
Premix membrane emulsification is a promising 
method to produce colloidal lipid carrier systems for 
intravenous administration with small particle sizes and 
narrow particle size distributions. In this procedure, a 
coarse pre-emulsion is repeatedly extruded through a 
nanoporous membrane leading to droplets in the 
nanometer range.  
In a previous study triglyceride oil nanoemulsions with 
particle sizes below 100 nm could be prepared with 
aluminium oxide membranes (Anodisc™ 0.02 µm) and 
sucrose laurate (SL) as a nonionic emulsifier. The long-
term stability of these nanoemulsions depended on the 
concentration of the emulsifier. The more sucrose 
laurate was used in the formulations the faster was the 
particle size growth induced by Ostwald ripening    
[El-Hawari, 2018]. Ariyaprakai and Dungan could also 
observe a negative effect of an excess of emulsifier 
[Ariyaprakai, 2010].  
Ostwald   ripening  is   the process   where   large 
droplets    grow   at   the    expense   of   smaller   ones  
due to the  higher solubility of the smaller particles. 
Simultaneously   the   particle   size   distribution    gets  
narrower which is a major  characteristic of Ostwald 
ripening. 
The aim of this study was to investigate the 
relationship between the emulsifier concentration, the 
concentration of free emulsifier (emulsifier in 
continuous phase, not bound to any interfaces) and 
Ostwald ripening to be able to forecast the composition 
of nanoemulsions that have a good stability and to 
learn more about the parameters influencing Ostwald 
ripening in the emulsions. 
RESEARCH CONCEPT 
The nanoemulsions were produced by premix 
membrane emulsification with an instrumented small 
scale extruder [Gehrmann, 2016]. The extruder consists 
of a high pressure syringe pump connected to a 
membrane holder and a computer to control the flow 
rate. A coarse premix emulsion dispersed with an 
Ultra-Turrax (IKA T25 digital, S25N-10G, Ika-Werke) 
at 10.000 rpm for 2 min was processed 27 times 
through Anodisc™ membranes (0.02 µm pore size,  
d= 41 mm) with a constant flow rate of 0.4 ml/s. The 
https://doi.org/10.24355/dbbs.084-202001220921-0
Symposium on Pharmaceutical Engineering Research SPhERe, 25 – 27 September 2019, Braunschweig/Germany 2 
emulsions consisted of 10 % Miglyol® 812 (MCT) and 
various concentrations of sucrose laurate        
(1.5-10 %) in double distilled water. Sodium azide 
(0.05 %) was added as a preservative. 
Two different production methods were used, termed 
“general method” and “addition method” in the 
following. In the general method the whole emulsifier 
was added to the aqueous phase at the beginning of the 
production. Using the addition method only 1.5 % 
emulsifier was added in the beginning and the 
difference to the defined concentration was added to 
the already prepared nanoemulsion under stirring for 2 
hours. The emulsions were stored for 18 weeks under 
nitrogen at 20°C and the particle size and particle size 
distribution was measured at particular times. 
The particle size (Z-Average diameter) and particle 
size distribution width (expressed as polydispersity 
index (PDI)) were determined using photon correlation 
spectroscopy (PCS) (Zetasizer Nano ZS, Malvern 
Instruments) at 25 °C and a backscattering angle of 
173°. The emulsions were diluted to an attenuator of 
6-8 and measured three times for 5 min with 5 min
equilibration time. The mean number average diameter
was determined applying the Mie theory (nlipid= 1.45,
nimag= 0.01, ncontin= 1.33) and used for the calculation of
the Ostwald ripening rates. The Ostwald ripening rate
ω was calculated from the cube of the number average
droplet radius as a function of time [Kabalnov, 1994].
The concentration of free emulsifier in the continuous 
phase of the nanoemulsions was measured after 
filtering 5 ml of the respective nanoemulsion  through 
Vivaspin® 6 tubes (Sartorius, MWCO 300 kDa) with 
the aid of centrifugation for about 20 min (500xg, 
22°C). Receiving a small volume of the continuous 
phase, without lipid droplets, the refraction index 
(Abbemat WR, Anton Paar) was measured and the SL 
concentration determined with the aid of a calibration 
curve. 
The critical micelle concentration (CMC) was 
measured by the surface tension method with a 
Wilhelmy plate at 25°C (Tensiometer K100, KRÜSS 
GmbH). A solution of SL was stepwisely added to 
double distilled water and the values were plotted on a 
logarithmic scale against the surfactant concentration. 
The CMC was determined at the intersection of the 
linear fits. 
RESULTS 
With the general method all emulsions were 
successfully prepared but with different initial particle 
sizes, all smaller than 100 nm depending on the SL 
concentration. The initial particle size got smaller with 
higher SL concentrations using the same production 
parameters. The reason is that more emulsifier has a 
better stabilisation effect during the emulsification 
process and therefore smaller particles can be 
generated. Upon storage the droplet sizes increased up 
to a maximum of 135 nm (depending on SL 
concentration).  The Ostwald ripening rates were 
linearly related to the SL concentration (Fig. 1) and in 
good agreement with results from earlier studies [El-
Hawari, 2018]. When using the general method for 
emulsion preparation the Ostwald ripening rates are 
affected by the different initial particle size which is 
likely to have an influence on the results.  
To tackle this problem an alternative processing 
method, the addition method, was tested. The particle 
size of the nanoemulsions was measured before and 
shortly after the second addition of SL. No significant 
alterations of the droplet sizes could be detected under 
these circumstances. After longer storage times a 
similar particle size growth as in emulsions prepared 
by the general method as well as decreasing PDI values 
could be measured. The Ostwald ripening rates were 
calculated and compared with that for emulsions 
prepared with the general method (Fig. 1). A linear 
relationship could also be determined for the addition 
method. 
To obtain more detailed information about the 
parameters influencing Ostwald ripening the 
concentration of free SL was determined. The Ostwald 
ripening rate had a linear relationship to the 
concentration of free SL. The more free SL was 
available in the continuous phase the faster was the 
Ostwald ripening (Fig. 2). With regard to the overall as 
well as to the free SL concentration the slope of the 
linear fit for emulsions prepared with the two different 
methods are not completely equal.  
The CMC (mean of three independent measurements) 
of SL was determined as 0.015%. 
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DISCUSSION 
Ostwald ripening similarly occurred in the emulsions 
prepared by the two methods but somewhat 
unexpectedly the correlation between Ostwald ripening 
rate and SL concentration was not the same. The 
smaller slope observed for emulsions prepared by the 
general method may be a consequence of the different 
initial particle sizes of the emulsions prepared with 
different emulsifier contents.  
Nevertheless, the higher the concentration of free SL 
the higher were the Ostwald ripening rates independent 
of the method. In these experiments the concentration 
of free SL seems to be the major factor determining the 
rate of Ostwald ripening. Different mechanisms have 
been discussed how the transport of lipid  through  the 
continuous phase may be going on. One possibility is 
the transport in micelles [Binks, 1999, Weiss, 2000]. 
The results obtained for  the concentration of free SL 
were, except for emulsions containing 1.5 % SL, above 
the critical micelle concentration (CMC= 0.015 %). 
Transport in micelles thus seems to be a likely 
possibility but further investigation is necessary to 
prove the underlying mechanisms. 
It is also an interesting point that the amount of SL 
bound to the interfaces (calculated from the difference 
of absolute concentration and free SL concentration) 
increased with higher SL concentration (Fig. 3). The 
curve progression leads to the assumption that at higher 
SL concentrations, a saturation of the interfaces will 
likely be reached. With regard to the storage stability 
nanoemulsions with less SL, e.g. 1.5 %, and therefore 
less SL bound to interfaces, were better stabilized 
against particle size growth as reflected by a low 
Ostwald ripening rate (Fig. 1). Higher surface coverage 
with emulsifier molecules does thus not have a 
protecting effect against Ostwald ripening of 
nanoemulsions. 
CONCLUSIONS 
For the emulsions under investigation here the free 
concentration of emulsifier is a main influencing 
parameter for the rate of Ostwald ripening probably by 
Fig. 1: Comparison of Ostwald ripening rates 
calculated for emulsions obtained by the general and 
the addition method at different SL concentrations. 
Fig. 2: Linear correlation between Ostwald ripening 
rates and the concentration of free SL for emulsions 
prepared with the general and the addition method.      
* values are affected by the presence of lipid droplets
in the filtrate.
Fig. 3: Correlation between the amount of SL bound 
to the interfaces and the overall SL concentration for 
emulsions prepared by the general and the addition 
method. * values are affected by the presence of lipid 
droplets in the filtrate. 
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its effect on micellar transport. In order to achieve  
long-term stable nanoemulsions the concentration of 
free SL should be about zero to minimize the Ostwald 
ripening rate. It seems to be of little importance for the 
speed of Ostwald ripening whether the emulsifier SL is 
completely added before processing (general method) 
or in two parts, before and after emulsification 
(addition method). The different initial particle sizes 
resulting from preparation with the general method 
probably affected the results obtained for the Ostwald 
ripening behaviour. The addition method can serve as 
an easy and time-saving method to produce 
nanoemulsions with the same particle size but different 
SL concentrations. 
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ABSTRACT 
Substances extracted from Cannabis varieties are of increasing interest, especially cannabidiol as a non-psychoactive 
drug with various pharmacological effects. Formulation of cannabidiol is, however, challenging due to its low water 
solubility. In this study, different types of lipid carriers were investigated as formulation options for cannabidiol to enable 
parenteral or oral application.  
The study included self-dispersing lipid formulations, nanoemulsions and liposomes. With regard to parenteral 
application, a higher load of cannabidiol was obtained in nanoemulsions than in liposomes. Lipid nanoemulsions are thus 
a very promising formulation option for parenteral formulations with a high drug load. Also in formulations intended for 
oral use a notably higher amount of cannabidiol could be incorporated in oil-containing self-dispersing formulations than 
in liposomes.  
Keywords: Cannabidiol, lipid carriers, lipid-based formulations 
INTRODUCTION 
Cannabidiol (CBD) is a natural compound isolated from 
Cannabis varieties which has, unlike Δ9-
tetrahydrocannabinol, not shown psychoactive 
behaviour [Perez-Reyes, 1973]. Interest in CBD has 
increased since the beginning of the 2000s and several 
pharmacological effects are discussed, such as anti-
inflammatory, anti-oxidative and neuroprotective 
action. It is further suggested that CBD might be 
beneficial in diseases such as Parkinson’s disease, 
diabetes, nausea, cancer, inflammatory diseases and 
several others [Zuardi, 2008]. How to formulate 
cannabidiol is therefore an intriguing question in order 
to enable the use of this promising drug substance. 
Formulations in lipid carriers are especially promising 
options due to the lipophilicity of cannabidiol with 
regard to both parenteral and oral administration. Lipid 
carriers with sizes in the nanometer range can enable 
parenteral administration in the therapy with CBD 
which could be of interest due to the wide field of 
pharmacological effects. For oral therapy, self-
dispersing lipid formulations can be generated using 
phospholipids as natural emulsifier and solubilizer. 
These formulations can be filled into hard capsules and 
disperse in the gastro-intestinal fluids due to mild 
agitation. 
RESEARCH CONCEPT 
The maximum amount of drug loaded into dispersed 
formulations was determined by passive loading, a 
formulation screening method [Göke, 2017; Rosenblatt 
2017]. Using this method, the powdered drug is 
incubated with the respective carriers in aqueous media 
and loads into the dispersed carriers by diffusion. The 
excess of drug is removed from the dispersion by 
filtration and the amount of loaded drug is analyzed.  
For loading experiments with oral formulations, 5 % 
self-dispersing formulation (38 % medium chain 
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triglycerides (MCT), 57 % Phospholipon 90 G, 5 % 
ethanol 96 %) was dispersed in phosphate buffer pH 7.0. 
5 % Phospholipon 90 G was dispersed accordingly to 
generate liposomes for a comparison. The dispersions 
were then treated with an ultrasonic probe to reduce the 
particle sizes to around 200 nm. Centrifugation and 
subsequent filtration removed titanium particles of the 
probe and coarse materials from the dispersion. The 
phospholipid content was then determined by Stewart 
assay [Stewart, 1980] to check how much lipid was 
removed by these steps. Briefly, samples were dried 
under a flow of nitrogen at 40 °C and then dissolved in 
chloroform. Phospholipids were quantified by 
colorimetric reaction with ammonium ferrothiocyanate.  
Liposomes for parenteral formulations were produced 
by membrane extrusion. 10 % Lipoid S 75 was dispersed 
in phosphate buffer pH 7.4 and, after stirring overnight, 
ten times extruded through a 0.1 µm polycarbonate 
membrane to achieve a particle size of around 90 nm (all 
particle sizes were determined by photon correlation 
spectroscopy).  
Emulsions for parenteral application were produced by 
high-pressure homogenization. The production of the 
trimyristin emulsion was carried out at 75 °C, all other 
emulsions were produced at room temperature. Lipid 
(5 % trimyristin, 10 % MCT or 10 % soybean oil) and 
aqueous phase (poloxamer 188, sodium azide, water) 
were weighed in and dissolved separately. Afterwards 
the phases were united and processed by an ultra-turrax. 
These pre-emulsions were homogenized ten times in a 
Microfluidizer. The pressure applied depended on the 
formulation, resulting mean particle sizes were between 
110 nm and 280 nm.  
Lipofundin (5 % soybean oil, 5 % MCT, egg 
phospholipids) is a commercially available parenteral 
fat emulsion.     
Cannabidiol was added to the respective dispersion 
which was placed on a shaker. In case of oral 
formulations, samples were drawn in several intervals 
and analyzed for drug content by UV spectroscopy at 
215 nm (solute tetrahydrofuran/acetonitrile (8/2)) until 
saturation. Lipid carriers for parenteral application were 
incubated in independent vials and the drug content was 
analyzed by UV spectroscopy at 212 nm (solute 
tetrahydrofuran/water (9/1)). 
RESULTS 
Cannabidiol showed a remarkably high drug load in 
lipid formulations (up to approx. 47 % in relation to the 
lipid content (Fig. 1)). 
In formulations for oral application, CBD was loaded to 
a significantly higher extent into the self-dispersing 
mixture than into liposomes. In parenteral formulations, 
the trimyristin emulsion showed a considerably higher 
CBD load compared to emulsions of other oils. Drug 
loading into the phospholipid- and thus charge-
stabilized Lipofundin emulsion led to a comparable drug 
concentration as for a sterically(poloxamer)-stabilized 
MCT emulsion. In the same manner as for oral 
formulations, cannabidiol reached a much higher 
concentration in all emulsions as compared to 
liposomes.  
DISCUSSION 
The very high drug load in the trimyristin emulsion 
indicates a lipid dependence of achievable CBD load in 
emulsions. This is in agreement with literature reports, 
where lipid dependence is also shown for other drugs 
[Göke, 2017]. A comparable drug load in the differently 
stabilized Lipofundin and MCT emulsion implicates 
that there is no strict preference of CBD for sterically or 
charge-stabilized emulsions. Higher drug loading in 
emulsions and self-dispersing mixtures compared with 
liposomes emphasizes an advantage of oil-containing 
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Fig. 1: Drug load of cannabidiol in parenteral 
formulations. 
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CONCLUSIONS 
Lipid nanoemulsions achieve a high load of cannabidiol 
and therefore enable parenteral administration. Due to 
the lipid-dependent drug loading, the choice of the lipid 
has to be taken into account upon formulation of CBD 
in nanoemulsions. Self-dispersing mixtures are a 
promising option as well, as they facilitate oral 
administration and can be loaded with high CBD 
concentrations, too. Liposomes are a less interesting 
option for CBD formulation as notably less drug 
substance loaded into these carriers.   
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MEASUREMENTS OF BIOLOGICAL FUNCTION. 
Früh E1,3, Bütefisch C1,3, Leester-Schädel M2,3, Gursky B2,3, Dietzel A2,3, Bütefisch S4 and Rustenbeck I1,3 
1Institute of Pharmacology and Toxicology, 2Institute of Microtechnology, University of Braunschweig, 
3PVZ-Center of Pharmaceutical Engineering and  
4PTB –Physikalisch-Technische Bundesanstalt/Federal Institute of Metrology, Braunschweig 
Contact: i.rustenbeck@tu-braunschweig.de, +49531391-5670, Mendelssohnstraße 1, 38106 Braunschweig, Germany 
ABSTRACT 
The model of the cultured single cell is considered insufficient to explain the physiological regulation taking place at the 
organ level. The same is true for the prediction of drug action at the organ level or at the level of the intact organism. For 
these reasons 3D cell culture models are in increasing demand. It is thus necessary to develop the instruments to handle 
such cell aggregates and organoids in a controlled, precise and gentle manner. Here, a microgripper is presented which is 
able to work in aqueous solutions and which is compatible with electrophysiological recordings of the cells immobilized 
by it. It was successfully employed to position isolated pancreatic islets and a 3D cell culture model of insulin-secreting 
cells, the so-called MIN6-pseudoislet. As required it was possible to measure the membrane potential of cells within these 
aggregates without any interference from the microgripper.  
Keywords: Diabetes mellitus, insulin secretion, Organ-on-chip, multiparametric measurements 
INTRODUCTION 
2D cell culture systems have been the workhorse for 
biomedical research for decades. However, it is 
increasingly becoming clear that this reductionist model 
of cellular physiology is insufficient to explain the 
regulation taking place at the organ level (1). In 
particular, it is insufficient to reliably predict the action 
of newly developed drugs in the intact organism (2). 
Consequently, 3D cell culture models are gaining in 
popularity and it is expected that more relevant 
information can be gathered from their use. However, 
the standard instrumentation in the cell biology 
laboratory is designed to deal with liquids and with cells 
suspensions but not with larger cell aggregates or 
organoids. In view of these tendencies it is imperative to 
develop the instruments to handle cell aggregates and 
organoids in a controlled, precise and gentle manner. 
Here we present the first version of a microgripper 
designed to deal with biological specimen.  
The microgripper was used to position isolated 
pancreatic islets and a 3D cell culture model, the so-
called MIN6-pseudoislet. Pancreatic islets contain 
multiple cell types, most notably the beta cells which 
synthesize and release insulin, the main glucoregulatory 
hormone of the human body (3). MIN6 cells are 
immortalized insulin-secreting cells, which share many 
similarities with the beta cells, but have a much higher 
tendency to proliferate (4).  
RESEARCH CONCEPT 
Microgripper The design of the microgripper is based on 
the microgripper toolbox developed at the IMT of the 
TU Braunschweig (5). To operate the microgipper in 
aqueous solutions and to be compatible with 
electrophysiological recordings of the cells immobilized 
by the gripper, the following design was chosen: The 
microgripper is fully made of SU-8, a UV sensitive, high 
contrast, epoxy based negative tone photoresist. Due to 
lithographic exposure with UV radiation and subsequent 
development and curing, the resin polymerizes. It is then 
fluid resistant and almost transparent. In order to prevent 
the electrophysiological investigations from being 
disturbed by the drive that opens and closes the gripper 
jaws, non-electrical actuator principles were selected 
and investigated. These are, on the one hand, a 
pneumatic and, on the other hand, a bowdencable based 
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actuator principle. The investigations described here are 
made with the latter principle. The total length of the 
gripper is 7.2 mm. The length of the gripper jaws is 
about 700 µm, and they can be opened to 400 µm. The 
actuator’s linear positioning movement is transmitted 
via an integrated gripper gear to the gripper jaws, so that 
they move evenly and parallel to each other, thus having 
a centering effect. This ensures a reliable holding 
process safety and an even load on the object to be 
gripped (Fig. 1). 
Cells and tissues Pancreatic islets of NMRI mice were 
isolated from the surrounding pancreatic exocrine tissue 
by a collagenase digestion technique. Isolated islets 
were collected under a stereomicroscope and were 
cultured overnight in cell culture medium RPMI1640 
with 10% fetal bovine serum (FBS) and 5 mM glucose. 
Insulin-secreting MIN6 cells (kindly provided by Jun-
Ichi Miyazaki) were cultured in DMEM medium 
(25 mM glucose, 6 mM glutamine), 10% FBS and 
penicillin/streptomycin in a humidified atmosphere of 
95% air and 5% CO2 at 37°C. 
Monitoring of islet function parameters: The plasma 
membrane potential and currents of single cells within 
islets or pseudo-islets were measured using the patch 
clamp technique (Fig. 2). Pipettes were pulled from 
borosilicate glass (2 mm o.d., 1.4 mm i.d., Hilgenberg, 
Germany) by a two-stage vertical puller (HEKA-
Electronics, Lambrecht, Germany) and had resistances 
between 3 and 6 MΩ when filled with solution. The 
continuous measurements of the membrane potential 
and membrane currents were performed using an EPC 7 
patch-clamp amplifier (HEKA-Electronics). 
Fig. 1 Microgripper holding and moving a MIN6 
pseudo-islet in the bath system of the patch clamp 
measuring stand 
Fig. 2 Patch-Clamp measuring stand with the micro-
gripper holder to the left of the organ bath 
(illuminated area) and the preamplifier to the right.  
Fig. 3 Microgripper holding a MIN6 pseudo-islet 
while a Giga-Ohm seal is formed by the patch pipette, 
permitting electrophysiological measurements.  
RESULTS 
The jaws of the present version of the microgripper were 
actuated by a newly developed actuation system based 
on a stepper motor, a fine positioner and a bowdencable-
like transmission system. With this actuation system the 
distance between the jaws could be adjusted extremely 
precise from 400 µm to a complete closed stage. This 
movement of the jaws generated a contact between the 
microgripper and the spheroid islet which was 
sufficiently stable to permit back and forth movements 
within the aqueous bath solution. The newest design of 
the microgripper is equipped with an integrated force 
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sensor to monitor the exerted gripping-forces. The 
determination of the exerted force by the jaws of the 
gripper is subject of current investigation (a calibration 
facility is currently under development). But it can be 
stated that the exerted gripping force only slightly 
deformed the islet shape. When MIN6 pseudo-islets 
were used it was difficult to establish a sufficiently 
stable contact, probably because they are more easily 
deformable. 
Placing a patch pipette (tip diameter ca. 1 µm) on one of 
the outer pseudo-islet cells (Fig. 3) and applying gentle 
suction (8 cm water) led to the build-up of a Giga-Ohm 
seal, as could be seen from the diminishing currents 
elicited by the -10 mV test pulse. This close connection 
between the cell membrane and the glass surface of the 
pipette is indispensable to measure the very small 
currents flowing through the ion channels of the plasma 
membrane. It is easily disturbed by even small 
movements of the cell surface relative to the tip of the 
pipette. In the present experiments a seal of more than 
1 Giga Ohm persisted reproducibly for more than 
15 min.  
DISCUSSION 
The present design of a mechanically actuated 
microgripper for 3D cell culture models fulfills several 
of the pre-defined requirements. It can generate a 
sufficiently firm contact to permit the positioning of the 
multicellular aggregates within cell culture media or 
other bath solutions. It does not interfere with the 
sensitive measurements of membrane currents and 
potentials. It is sufficiently stable to permit extended 
periods of measurement. The more pronounced 
difficulties in handling the pseudo-islets suggest that 
changes in the jaw design may be necessary to deal with 
mechanically less stable cell aggregates.  
CONCLUSIONS 
The present microgripper demonstrates the feasibility of 
using this kind of instrumentation to handle 
multicellular aggregates. In particular, a good long-term 
stability is achieved. This now enables further 
development such automated pick and place using 
integrated object recognition.  
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CO2 EXTRACTION – A PRODUCTION PROCESS FOR THE RECOVERY OF API 
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ABSTRACT 
The desired valuable ingredients determine the required solvent. After some thermodynamic consideration about 
supercritical fluids and the advantages of liquid and supercritical carbon dioxide for extraction purposes some exceptional 
examples for the recovery of active pharmaceutical ingredients of medicinal plants are discussed. 
Keywords: CO2 extraction, active pharmaceutical ingredients, medicinal and aromatic plants 
INTRODUCTION 
Plant extracts are used in many fields of human life. The 
use as API in natural remedies, in functional foods or 
nutraceuticals or in natural cosmetics asks for 100% 
natural extracts. The versatile CO2-extraction 
technology can help to satisfy the demands for tailor-
made highly concentrated pure extracts. CO2 extracts, 
with their unique spectrum of ingredients composed of 
non-polar secondary plant metabolites, offer new 
possibilities especially where quality and added value 
are important. 
EXTRACTION SOLVENTS AND THEIR 
PROPERTIES 
The production of plant extracts requires solvents. 
European legislation regulates the use of extraction 
solvents. Only a small number of solvents is allowed. 
For certified organic products only the solvents water, 
ethanol and carbon dioxide can be used. For the 
extraction of plant material the desired valuable 
ingredients determine the required solvent. For the 
recovery of pure lipophilic and less polar components 
CO2 extraction is an established process. If the 
extraction of more polar components like steroids,  
phenolic compounds or phospholipids is desired then it 
is of advantage to mix some percent of ethanol into the 
carbon dioxide. 
Fig 1: Thermodynamic state of an auxiliary material in 
separation procedures [Stahl 1986] 
The CO2 extraction method generates many positive 
properties. The selectivity of the solvent is adjustable by 
pressure and temperature in the extraction step. CO2 
works under gentle process conditions, sensitive 
ingredients can be recovered without thermal stress or 
oxidative degradation. Supercritical CO2 has very good 
mass transfer properties, with a viscosity and a diffusion 
coefficient like a gas it has a density like a liquid. As a 
consequence high CO2 flow rates allow short extraction 
times and this results in a favourable impact to the 
process costs. The frequently reported disadvantage of 
supercritical CO2 extraction, the cost of the process, 
https://doi.org/10.24355/dbbs.084-202001220921-0
Symposium on Pharmaceutical Engineering Research SPhERe, 25 – 27 September 2019, Braunschweig/Germany 2 
needs to be put into context. The quality of the CO2 
extracts is unachievable with other extraction methods 
and the CO2 extracts are usually part of new products. 
Table 1: Solvent selection. 
EXCEPTIONAL EXAMPLES 
After a survey of the use of CO2 extracts from botanicals 
in products of the daily life some exceptional examples 
are discussed. Flowers of the well known medicinal 
plants camomile, calendula or arnica are source material 
for the CO2 extraction of products for natural remedies. 
CO2 extracts of the roots of echinacea varieties are 
useful ingredients for medicinal skin care and boosting 
the immune system. A lot of medicinal and aromatic 
plants are extracted with supercritical CO2 and these 
extracts are filled in capsules for convenient dietary 
supplements. Guggul CO2 extract, from the gum of 
Commiphora mukul tree, is prepared with a supercritical 
CO2 – cosolvent extraction with ethanol and recovers the 
active constituents that show tremendous promise for 
human well-being. The CO2 extraction of some of these 
examples is described in more detail. 
Table 2: examples of the use of medicinal plant extracts 
MAP Plant part Active 
ingredients 
Calendula Flower Faradiolesters 
Arnica Flower Sesquiterpen-
lactones 
Oregano Leaf Carvacrol, 
thymol 













Supercritical CO2-extraction is a state of the art 
technology to recover highly concentrated pure extracts. 
CO2 extracts can be used as API in pharmaceuticals but 
they have to be licensed. In Europe CO2-extraction is 
meanwhile a standard method to produce extracts for 
food supplements or cosmetic ingredients, but only a 
few plants have the permission for pharmaceuticals 
because of the need for GMP processing. 
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PELLETS 4.0 – ADVANCED FLUIDIZED BED TECHNOLOGIES 
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INTRODUCTION 
Fluid bed processes were first developed for the 
chemical industry to achieve better drying efficiencies 
than obtained with existing technologies e. g with tray 
drying. Implementation of spray nozzles in the fluid bed 
equipment enabled granulation processes, resulting in 
porous agglomerates and, processed to tablets, 
facilitating fast dissolution. With the development of the 
bottom spray technology highly efficient coating and 
layering processes became possible. While in the 
beginning this technology was mainly used for tablet 
coating, more and more processes were developed for 
coating of smaller particles, i. e. multiparticulates like 
pellets, minitablets and powders (e. g. API crystals).  
Multiparticulate dosage forms consist of small discrete 
units with particle sizes of 100 – 2000 µm [1] showing 
a matrix structure (API implemented in the core) or 
being API layered. In case of pellets or minitablets, 
functional coatings can be applied, resulting in taste 
masking, gastroresistant coatings or other specific 
release profiles. Filling of multiparticulates into 
capsules or sachets and administration via sprinkling on 
liquids or food makes them attractive for patients who 
are not able to swallow monolithic dosage forms, as is 
the case for children or elderly. The possibility of 
administering different amounts of multiparticulates 
provides an opportunity for the development of 
individualized medicines. Also a compression into 
tablets is possible, orally disintegrating tablets (ODTs) 
release their discrete units in the stomach, ensuring a 
controlled drug release and less dependency on the 
gastric emptying. 
Glatt offers several batch-wise or continuous 
technologies for the production of multiparticulates, 
matrix or layered pellets. Process development and 
optimization can be performed with quality by design 
approaches, process monitoring and control by state of 
the art PAT tools. The presentation will give an 
overview about the recent and most prevalent 
manufacturing methods. 
BATCH FLUID BED TECHNOLOGIES 
WURSTER TECHNOLOGY 
The Wurster technology [Figure 1] is a classic fluid bed 
technology used for drug layering and (functional) 
coating of even very small multiparticulates and 
powders. The layering or coating liquid is sprayed 
concurrently with the fluidization air into the circulating 
fluid bed. The liquid is frequently and repeatedly applied 
as droplets on the substrate [Figure 1] in an environment 
of high heat transfer, finally resulting in a dense coating. 
Figure 1: Wurster technology, coating process (Glatt 
Pharmaceutical Services GmbH & Co. KG) 
CPSTM TECHNOLOGY 
The CPSTM technology [Figure. 2] allows the 
preparation of both high drug loaded as well as low 
dosed matrix pellets, with sizes down to 150 µm. Based 
on advanced fluid bed rotor technology, the CPSTM 
technology works with a conical shaped rotating disc 
https://doi.org/10.24355/dbbs.084-202001220921-0
Symposium on Pharmaceutical Engineering Research SPhERe, 25 – 27 September 2019, Braunschweig/Germany 2 
and devices providing a directed product flow. No 
starting beads are required. The powder, containing API 
and typically microcrystalline cellulose is wetted by the 
pelletizing liquid until a pre-defined moisture level (and 
with this: particle size) is obtained. Due to centrifugal 
forces, spherical particles are formed and densified, 
characterized by smooth surfaces, narrow particle size 
distribution [Figure 3] and low porosity and attrition.  
Figure 2: CPSTM technology, pelletizition process (Glatt 
Pharmaceutical Services GmbH & Co. KG) 
Figure 3: Matrix pellets produced with CPSTM 
technology (left), and MicroPxTM technology (middle, 
and right, Glatt Pharmaceutical Services GmbH & Co. 
KG) 
CONTINUOUS FLUID BED TECHNOLOGIES 
MICROPXTM / PROCELL TECHNOLOGY 
The MicroPxTM technology is the preferred option for 
the production of high drug loaded pellets with API 
contents up to 95%. Spherical and smooth particles in 
the size of 150 µm or bigger can be obtained [Figure 3], 
exhibiting narrow particle size distributions. In this 
continuous process, the API containing liquid (solution, 
suspension, emulsion, melt [2]) is sprayed into the 
empty process chamber. Initially, fine powder is 
generated by spray drying, which is continuously 
agglomerated to seeds, and by further layering, to round 
pellets. Well-sized pellets are discharged by a sifter; the 
classifying air determines the resulting particle size. The 
process is characterized by a balanced ratio between 
spray drying, layering and discharging of well-sized 
pellets.  
In contrast to the MicroPxTM technology the process gas 
enters the process chamber in the ProCellTM not through 
an inlet air distribution plate, but through slots in the 
lower part of the equipment, resulting in a spouted bed 
[Figure 4]. The contact of the product to hot surfaces is 
minimized, therefore this technology is applicable also 
for heat sensitive substances like enzymes. 
Figure 4: MicroPXTM (left) and ProcellTM (right)
technology, pelletization process (Glatt Pharmaceutical 
Services GmbH & Co. KG) 
PROCESS CONTROL 
For the implementation of robust and reproducible 
production processes, the critical quality attributes for a 
manufacturing process shall be known [3]. After a risk 
analysis, a design of experiments (DoE) with planned 
trials is applied, to define the design space and a control 
strategy for selected process parameters. PAT tools e. g. 
for online measurement of moisture, API content and 
particle size distribution can be applied for automated 
end point detection, to reduce the offline control and 
release testing. 
SUBSCRIPT 
API Active pharmaceutical ingredient 
DoE Design of experiments 
ODT Oraly disintegrating tablet 
PAT Process analytical technology 
QbD Quality by Design 
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STABILITY TESTS OF ALKYNYLGOLD(I)(NHC) COMPLEXES BY HPLC-DAD-MS 
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ABSTRACT 
Gold organometallic compounds have been extensively investigated as potential anticancer metallodrugs and have shown 
a high potential regarding antiproliferative effects [Hickey, 2008; Andermark, 2016; Meyer, 2012; Schmidt, 2019]. 
Enhanced stability is a driving argument for the design of gold complexes with N-heterocyclic carbene (NHC) ligands. 
The more surprising is the lack of methods of pharmaceutical analytics for their stability and solution chemistry. Such 
analytical methods are important key elements for future metabolomic investigations and will help to ensure a better 
understanding of the biological behavior of the complexes [Kostiainen, 2003].   
We selected complexes of the type of alkynylgold(I)(NHC) for detailed stability studies by HPLC-DAD-MS, in 
comparison to the well-known antirheumatic drug Auranofin. A RP-based chromatographic method was established to 
separate possible degradation products of alkynylgold(I)(NHC) complexes. The stability studies were performed at 37°C 
over 24h using dimethylformamide (DMF), dimethyl sulfoxide (DMSO), water and Dulbecco`s modified eagle medium 
(DMEM) solutions of each compound. Furthermore, interaction experiments of alkynylgold(I)(NHC) complexes with 
acetylcysteine are under way with the same set-up as the stability tests [Albert 2012].       
ESI (+) and (-) ionisation with a quadrupole analyser was used for mass spectrometry. The first results indicate that 
alkynylgold(I)(NHC) complexes are stable in the analysed solvents with no significant changes in their AUCs [Fig 2].
INTRODUCTION 
N-heterocyclic carbene (NHC) ligands with their strong
σ-donating character can be coordinated well to several
transition metals. Specifically, gold(I) complexes have
been extensively investigated and have shown a high
potential regarding antiproliferative
effects [Hickey, 2008; Andermark, 2016; Meyer, 2012;
Schmidt, 2019]. The enhanced stability has been a
driving argument for the design of metal-NHC based
drugs. However, extended studies on their solution
chemistry and stability have not been frequently
performed and aspects of pharmaceutical analytics have
not been considered sufficiently. We selected complexes
of the type alkynylgold(I)(NHC) (Fig. 1) for detailed
stability studies by HPLC-DAD-MS, in comparison to














Figure 1: Structures of selected alkynylgold(I)(NHC) 
complexes 
On top of that an interaction experiment of 
alkynylgold(I)(NHC) complexes with acetylcysteine is 
under way with the same set-up as the stability tests. 
EXPERIMENTAL 
The stability studies were performed in four different 
solvents (DMF, dimethyl sulfoxide (DMSO), water and 
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Dulbecco`s modified eagle medium (DMEM)) and were 
carried out with an established HPLC method. The first 
step was to prepare a DMF stock solution, which was 
diluted with the respective solvent. For the stability tests 
in water and DMEM the organic solvent (DMF) amount 
had to be increased to 50% of the total volume because 
of the poor water solubility properties of the compounds. 
After transferring the solutions into the HPLC vials the 
incubation at 37°C was done in the auto-sampler unit of 
the HPLC. The time-dependent injection could be 
automated. For this study the injection was done after 
0h, 4h, 8h, 12h and 24h. 
The interaction experiment was performed in three 
different solvents: water, phosphate-buffered saline 
(PBS), 2-amino-2-(hydroxymethyl)propane-1,3-diol 
(Tris) buffer. Initially acetylcysteine and the 
alkynylgold(I)(NHC) complexes were characterized in 
the solvents mentioned above over a time period of 24 
hours. After the characterization an equimolar solution 
of acetylcysteine and each alkynylgold(I)(NHC) 
complex were prepared and incubated together at 37°C 
over 24 hours in the autosampler unit. The injections 
were automated and measured under the same 
conditions as the stability tests.      
DISCUSSION AND CONCLUSIONS 
Over the exposure time no significant peak changes 
were observed. Moreover, the peak areas remained 
unaltered over 24 hours. 
In the case of the interaction experiment a different 
behavior could be observed. In water the peak for the 
alkynylgold(I)(NHC) complex disappeared almost 
completely after 2h and a new peak with a much shorter 
retention time occurred in the chromatogram, which 
could be identified as Au(NHC)2+ by means of MS 
detection. A similar behavior can be observed in PBS 
and Tris buffer. In case of PBS the decrease of the main 
peak is much lower and even after 24h a significant 
amount of alkynylgold(I)(NHC) complex is still present 
in the sample. Almost the same behavior can be 
observed in Tris buffer, however, the effect is much less 
developed.   
NOMENCLATURE 
AUC area und curve 
DAD diode array detector 
DMEM Dulbecco`s modified eagle medium 
DMF  dimethylformamide 
DMSO dimethyl sulfoxide 
ESI  electrospray ionisation 
HPLC high performance liquid 
chromatography  
MS mass spectrometry 
NHC N-heterocyclic carbene
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ABSTRACT  
Considering the numerous organizational and legislative issues associated with in vivo studies, the present study aimed 
to develop in vitro tape stripping protocol that could serve as a prospective technique for skin penetration studies. The 
research was mainly focused on the suitability of transepidermal water loss (TEWL) measurements, as a barrier 
integrity test for porcine ear skin subjected to freezing/thawing procedure, as well as on the selection of the most 
suitable device for pressing adhesive tapes onto the porcine ear surface during skin stripping procedure. Obtained 
results suggest that TEWL measurements were able to detect the damage of the stratum corneum (SC) caused by 
physical impairment (using adhesive tapes) and tissue degradation/dehydration (prolonged storage at –20ºC/ambient 
conditions). Penetration profiles of aceclofenac from nanoemulsions based on sucrose esters or polysorbate 80 as 
coemulsifiers, obtained in vitro (using a roller as pressure device), were in a good agreement with data obtained in vivo 
on humans, supporting the use of developed in vitro tape-stripping protocol in skin formulation development and 
optimization. 
Keywords: tape stripping, porcine ear skin, nanoemulsions, in vitro-in vivo correlation, aceclofenac 
INTRODUCTION 
The rational approach for designing and optimizing 
novel skin formulations requires the use of well-
defined method, which can enable the assessment of 
drug penetration into the skin. Among different 
techniques proposed, tape stripping stands out as a 
simple and minimally invasive technique for the 
assessment of drug dermal availability in vivo, in 
humans. However, considering that in vivo studies are 
frequently associated with numerous organizational 
and legislative issues (e.g. the need for complex 
documentation when applying for ethical committee 
approval, particularly for nanocarrier testing), the 
research efforts have been directed towards the 
validation of porcine ear skin as an alternative in vitro 
model for human studies [Klang, 2012; Leal, 2017]. 
Having in mind some unresolved issues, such as (i) the 
capability of applying TEWL measurements in 
assessing the integrity of the porcine ears subjected to 
freezing/thawing procedure and (ii) the selection of the 
most suitable device for pressing adhesive tapes onto 
the skin surface, the aim of present study was to 
develop the in vitro tape stripping working protocol 
that could be simply used in the averages laboratories, 
without the need for sophisticated equipment. Recently 
developed nanoemulsions intended for topical 
administration of aceclofenac (ACF) [Isailović, 2016] 
were utilized to assess the applicability of suggested 
protocol for the analysis of small variations in 
formulation composition on ACF delivery into the 
skin, by comparing with corresponding results obtained 
in vivo on humans. 
RESEARCH CONCEPT 
Development of in vitro tape stripping working 
protocol – evaluation of selected critical steps 
Fresh porcine ears obtained from the local abattoir 
immediately after slaughter (before scalding), were 
washed under cold running water, blotted dry with the 
soft tissue, wrapped in the aluminum foil and stored at 
–20°C until use (within one to six months to evaluate
the effect of storage duration on skin barrier integrity).
On the day of experiment, after defrosting, hairs were
shortened with scissors and when TEWL reached the
values of approximately 15 gm-2h-1 (measured using a
Tewameter® TM 210, Courage+Khazaka, Germany),
ears were fixed on styrofoam plates [Klang, 2012]. In
order to evaluate the capability of TEWL
measurements to detect the changes in skin barrier
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function of defrosted porcine ears, periodic 
measurements of TEWL were performed during the 
progressive removal of the SC by adhesive tapes. 
Additionally, the TEWL measurements were 
performed on intact porcine ears periodically during 6 
h of storage at ambient conditions, in order to detect 
the potential changes in skin barrier (due to tissue 
dehydration). Additionally, since application pressure 
is one of the basic factors influencing the amount of SC 
removed during the tape stripping procedure, two 
different methods (roller vs. weight of 300 g) were 
examined regarding the impact on TEWL and total 
quantity of ACF and SC removed with each tape.  
In vitro tape stripping – a case study 
In order to assess the applicability of developed 
protocol to detect the potentially meaningful 
differences in ACF penetration in the SC from 
nanoemulsions differing in the both, type and 
proportions of surfactants employed for stabilization 
(table 1), tape stripping was performed in vitro under 
infinite dose conditions and correlated with the results 
previously obtained in vivo on human volunteers 
[Isailović, 2016]. Briefly, when TEWL reached the 
values of ~15 gm-2h, investigated formulations were 
carefully distributed on assigned skin sites. After a 2 h 
incubation period, the residual formulations were 
gently removed with dry cotton swabs, and 12 adhesive 
D-squame® discs (CuDerm Corporation, USA) were
utilized for sequential removal of SC layers, after being
submitted to uniform pressure using a roller device.
Table 1: Composition of investigated nanoemulsions, 
prepared using high pressure homogenization method 
Excipients 




MCT* 10 10 
Castor oil 10 10 
Egg lecithin 2/1/1.5 2 
Sucrose stearate  -/1/0.5 / 
Sucrose palmitate  2 
Polysorbate 80 / 2 
BHT* 0.05 0.05 
Aceclofenac 1 1 
Ultrapure water to 100 100 
* MCT – medium chain triglycerides, BHT –
butylhydroxytoluene
After removal of SC layers, each tape was transferred 
into a centrifuge tube and ACF was extracted with 4 
mL of ethanol (70%, v/v). The tubes were sonicated 
(Sonorex RK 120H, Bandelin, Germany) for 15 min 
and then centrifuged at 4000 rpm for 5 min (Centrifuge 
MPW-56; MPW Med. Instruments, Poland). 
Supernatants were analyzed for ACF content using 
UHPLC-MS/MS method [Isailović, 2016]. Validation 
of the extraction procedure was performed by spiking 
tape-stripped samples of untreated SC with the known 
quantity of ACF dissolved in ethanol (70%, v/v). After 
solvent evaporation, the extraction procedure was 
carried out as described above and drug recovery was 
determined. It was found that ACF recovery from the 
SC was 95.8 ± 2.9%.  
RESULTS 
During tape stripping procedure, TEWL progressively 
increased as barrier function was perturbed by 
sequential removal of SC layers (figure 1). However, 
TEWL increased only slightly during the removal of 
40% of the barrier’s thickness, but changed more 
noticeably when more than 50% of SC was removed 
(removal of ~80% of SC was accompanied with ~5-
fold increase of TEWL). 
Figure 1: Relative TEWL (measured TEWL divided 
by pre-stripping value) as function of relative SC depth 
Despite freezing/thawing procedure, the plots of 
1/TEWL versus SC were highly linear for ears stored 
up to one month in the fridge (mean r2 for six ears was 
0.9723; representative plot is shown at figure 2), 
enabling the total thickness of SC (L) to be calculated 
as described previously using Fick’s first law 
[Herkenne, 2006]. Interestingly, after three months (or 
more) storage of porcine ears at –20ºC, a linear 
correlation was deteriorated (r2 = 0.8182, n=6), 
suggesting that prolonged storage impairs the barrier 
function of porcine ear skin. 
https://doi.org/10.24355/dbbs.084-202001220921-0
Symposium on Pharmaceutical Engineering Research SPhERe, 25 – 27 September 2019, Braunschweig/Germany 3 
Figure 2: Representative linear plot of 1/TEWL as a 
function of the cumulative thickness of SC removed 
Periodical TEWL measurements during 6 h-storage of 
porcine ears at ambient conditions revealed that TEWL 
values declined sharply 4 h after reaching the desired 
value of ~15 gm-2h-1, due to the tissue dehydration.  
Figure 3: Quantity of ACF removed with each 
adhesive tape, reflecting the influence of different 
pressure device (roller vs. weight) 
Further, TEWL values obtained during tape stripping 
performed using roller device were significantly higher 
compared to those obtained using weight (after 12th 
removed tape, TEWL was 54.1 and 37.2 gm-2h-1, 
respectively). Simultaneously, significantly higher 
thickness of SC was removed when roller was used to 
exert the pressure on the adhesive tape. Importantly, 
significantly higher amount of ACF was extracted from 
the SC when roller was used, clearly showing the 
gradual decrease of ACF quantity with increasing the 
number of removed tapes (figure 3). 
Biocompatible aceclofenac-loaded nanoemulsions – 
a case study 
ACF concentration versus relative SC depth profiles 
obtained after 2 h-application of investigated 
nanoemulsions on the porcine ear skin are shown in 
figure 4. Firstly, it could be seen that nanoemulsions 
based on sucrose esters as coemulsifiers enhanced 
cutaneous penetration of ACF, showing the higher drug 
levels at all depths into the SC in comparison with 
reference prepared with the polysorbate 80. However, 
due to high variability of obtained data, statistical 
significance was found only between L1.5S0.5P2A and 
L2P802A formulations. Looking strictly at results 
obtained for sucrose esters-based nanoemulsions, 
investigated formulations could be ranked in the 
following order: L2P2A < L1S1P2A < L1.5S0.5P2A.  
Figure 4: Comparative ACF penetration profiles across 
the SC path-length L (mean ± SD, n = 4)  
Comparing the results obtained on porcine ears with 
results obtained in vivo, on human volunteers 
[Isailović, 2016], it could be noticed that results 
obtained in vitro are associated with significantly 
higher variability, probably due to difficulty in 
controlling the age, sex and way of pigs’ nutrition.  
Figure 5: Correlation of the total amount of ACF 
recovered in the SC in vitro (porcine ear skin) and in 
vivo (human voluneteers)  
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When the total quantity of ACF recovered in the SC in 
vitro 2 h after nanoemulsions application were plotted 
against the total amount of ACF inside the SC in vivo, 
a high correlation was observed (figure 5). 
Formulations with comparatively high amounts of ACF 
in the SC in vivo were associated with the greater 
penetration of ACF into the SC in vitro. 
DISCUSSION 
Despite the increased number of publications dealing 
with in vitro tape stripping, the literature data regarding 
the use of TEWL for skin barrier integrity assessment 
are quite controversial. The average SC thickness of 
defrosted porcine ears determined using TEWL 
measurements was 10.9 ± 3.2 µm, which was in 
accordance with literature data for SC thickness of 
fresh porcine ears (11.8 ± 4.0 µm) [Sekkat, 2002; 
Herkenne, 2006], proving the usefulness of TEWL 
measurement for skin barrier monitoring during tape 
stripping procedure in spite of freezing/thawing 
procedure. Furthermore, TEWL measurements enabled 
to detect changes in skin barrier function due to tissue 
degradation (caused by prolonged storage at –20ºC) 
and dehydration (caused by prolonged skin storage at 
ambient conditions). These findings indicate that 
porcine ears should be stored up to one month at –
20ºC, simultaneously proving that the isolated porcine 
ear could be a suitable model for the short-time 
application studies [Klang, 2012]. 
Analyzing the literature data dealing with in vitro tape 
stripping technique, it can be observed that different 
devices were utilized to press the tapes onto the skin 
surface. Obtained results suggest that the roller is better 
option than weight of constant mass. During the rolling 
movement, it appears that the skin surface flattens, 
enabling the optimal adhesive bond of the tape with the 
skin surface [Herkenne, 2006].  
Penetration profiles of ACF from developed 
nanoemulsions obtained in vitro using developed 
protocol, in spite of relatively high variability, were in 
a good agreement with previously published in vivo 
results, obtained under infinite dose conditions. Since 
all tested nanoemulsions exhibited the similar 
physicochemical parameters that are considered as a 
crucial for drug delivery into the skin (droplet size ~ 
180 nm, zeta potential ~40 mV, pH ~3.5, viscosity ~3.5 
mPa s), these findings confirmed that perturbation of 
the SC barrier by surfactants employed for 
nanoemulsion stabilization was primary mechanism 
responsible for observed differences in ACF skin 
penetration profiles. In the other words, it seems that 
sucrose esters are more efficient as skin penetration 
enhancers than conventionally used polyethoxylated 
surfactants such as polysorbate 80.  
CONCLUSIONS 
In vitro tape-stripping of developed protocol permits 
good prediction of drug uptake into the SC in vivo and 
therefore it may be highly useful in skin intended drug 
formulation development and optimization.  
ACKNOWLEDGMENT 
This work was supported by the project TR34031, 
funded by Ministry of Education, Science and 
Technological Development, Republic of Serbia.  
REFERENCES 
[Herkenne, 2006] Herkenne, C., Naik, A., Kalia, Y.N., 
Hadgraft, J., Guy, R.H., 2006, Pig ear skin ex vivo as a 
model for in vivo dermatopharmacokinetic studies in 
man, Pharm. Res.Vol. 23, pp. 1850–1856. 
[Isailović, 2016] Isailović, T., Đorđević, S., Marković, 
B., Ranđelović, D., Cekić, N., Lukić, M., Pantelić, I., 
Daniels, R., Savić, S., 2016, Biocompatible 
nanoemulsions for improved aceclofenac skin delivery: 
formulation approach using combined mixture-process 
experimental design, J. Pharm. Sci. Vol. 105, pp. 308–
323. 
[Klang, 2012] Klang, V., Schwarz, J.C., Lenobel, B., 
Nadj M., Auböck, J., Wolzt, M., Valenta, C., 2012, In 
vitro vs. in vivo tape stripping: validation of the 
porcine ear model and penetration assessment of novel 
sucrose stearate emulsions, Eur. J. Pharm. Biopharm. 
Vol. 80, pp. 604–614. 
[Leal, 2017] Leal, L.B., Cordery, S.F., Delgado-
Charro, M.B., Bunge, A.L., Guy, R.H., 2017,. 
Bioequivalence methodologies for topical drug 
products: in vitro and ex vivo studies with a 
corticosteroid and an anti-fungal drug, Pharm. Res. 
Vol. 34, pp. 730–737. 
[Sekkat, 2002] Sekkat, N., Kalia, Y.N,, Guy, R.H., 
2002, Biophysical study of porcine ear skin in vitro and 
its comparison to human skin in vivo, J. Pharm. Sci. 
Vol. 9, pp. 2376–2381. 
https://doi.org/10.24355/dbbs.084-202001220921-0
Symposium on Pharmaceutical Engineering Research SPhERe, 25 – 27 September 2019, Braunschweig/Germany 1 
APPLICATION OF LOWER PUNCH VIBRATION TO IMPROVE THE MECHANICAL 
STABILITY OF TABLETS 
Alexander Kalies1, Thomas Heinrich2, Claudia S. Leopold1 
1University of Hamburg, Division of Pharmaceutical Technology, Bundesstr. 45, 20146 Hamburg, Germany 
Alexander.Kalies@uni-hamburg.de (corresponding author) 
2Fette Compacting GmbH, Grabauer Str. 24, 21493 Schwarzenbek, Germany 
ABSTRACT 
A sufficient mechanical stability of tablets to be compacted prevents problems during tableting (e.g. sticking, capping, 
lamination) and is crucial with regard to further processing steps such as coating or packaging. Often, an improvement of 
the mechanical stability is only achievable by an adaption of the production settings (die disk speed) or an alteration of 
the powder blend composition. In the present study, a novel lower punch vibration device was developed and implemented 
on a rotary tablet press to improve the mechanical stability of the resulting tablets without changing the production 
conditions or the powder formulation. Various types of microcrystalline cellulose with different physical properties were 
selected. The powders were investigated concerning their powder flow, density, particle morphology and surface area and 
the tablets concerning their weight, tensile strength, and capping index. The results showed that externally applied lower 
punch vibration improved the mechanical stability of the investigated tablets beyond the adaption of the production 
settingss and the physical properties of the powder blend. 
Keywords: Tableting, lower punch vibration, mechanical stability, lamination.
INTRODUCTION 
The mechanical stability of a tablet is an important 
attribute and affects further handling steps of the tablet 
such as coating, packaging, and the end use by the 
patient. An insufficient mechanical stability of tablets is 
often caused by tablet failures such as capping or 
lamination. Capping describes the detachment of the top 
or bottom part of the tablet, whereas lamination is 
characterized by horizontal micro cracks [Mazel, 2015]. 
The reasons for the occurrence of these phenomena are 
complex and depend on the powder blend properties 
(deformation properties, relative density, 
compressibility) and/or the process settings (rotor speed, 
compaction force, tooling). In the past, only few solution 
approaches were introduced to reduce the capping or 
lamination tendency and to improve the mechanical 
stability of the tablet without changing the process 
conditions or altering the composition of the powder 
blend [Levina, 202]. A new promising approach to 
reduce or prevent tablet failures might be the application 
of externally lower punch vibration. Preliminary studies 
revealed that lower punch vibration during the die filling 
step enables the densification of the powder bed within 
the die leading to a different particle arrangement 
[Kalies, 2019]. Thus, the aim of the present study was to 
investigate in more detail the effect of external lower 
punch vibration under production conditions with regard 
to the mechanical stability of the resulting tablets. 
RESEARCH CONCEPT 
Materials 
Microcrystalline cellulose (Parmcel 102, Parmentier, 
Germany; MC-12, Blanver, Brasilia; Vivapur® 200, JRS 
Pharma, Germany; Avicel® 301, FMC, USA), 
magnesium stearate (Lehmann & Voss, Germany). 
Methods 
Powder Characterization 
According to the Ph. Eur., the bulk and tapped-density 
(jolting volumeter, Stav 2003, J. Engelsmann, 
Germany), the true density (helium pycnometer; 
AccuPyc 330; Micrometrics, Germany) and the relative 
density (bulk density / true density) were determined. 
The powder flow was characterized by the Hausner 
ratio, the compressibility index, and by ring shear cell 
measurements (RST-XS, Dr. Dietmar Schulze 
Schüttgutmesstechnik, Germany). Hence, the powder 
flow function (FFC) was examined at a mean 
consolidation stress of 5.0 kPa and calculated as 
follows: 
 FFC = Consolidation stressUnconfined yield strength    (1) 
In addition, the particle shapes were visualized with a 
scanning electron microscope (LEO 1525, Carl Zeiss, 
Germany) and the particle size distributions were 
determined with a laser diffractometer (Helios, 
Sympatec, Germany). 
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Tablet Characterization 
The investigated tablets were analyzed with a 
multifunctional hardness tester (TBH 525; Erweka, 
Heusenstamm, Germany) with regard to their weight, 
thickness and crushing strength. Afterwards, the tensile 
strength (Eq. 2), and capping index (Eq. 3) were 
calculated. 
 σ = 2 ∙ Fπ ∙  d  ∙  t   (2) 
where F is the crushing force (N), d the tablet diameter 
(mm), and t the tablet thickness (mm). 
Capping Index = (5 ∙  Nop + Nh)Nt  (3) 
where Nop is the number of capped/laminated tablets 
after tableting, Nh the number of capped/laminated 
tablets during hardness testing, and Nt the total number 
of investigated tablets. 
Tableting 
Tableting was performed in single punch mode on a 
Fette 102i rotary tablet press with 10 mm flat faced 
punches. An automatically rotating filling wheel was 
used as filling unit. Before tableting, 0.5 % (w/w) of 
magnesium stearate was added to the powder blends 
which were mixed for 3 min. The target tablet weight 
was approximately 300 mg for each powder blend. The 
vibration equipment, described by Kalies et al. [Kalies, 
2018], was composed of a modified filling cam and an 
externally mounted pneumatic turbine vibrator (MTT 
13; Mooser, Germany). 
RESULTS 
The determined physical powder properties are listed in 
Table 1.  
Table 1: Physical properties of the investigated MCC 
types. 
The resulting tensile strengths of the tablets 
manufactured conventionally and by application of 
lower punch vibration are displayed in Fig. 1A and B, 
respectively. Obviously, the tensile strength decreased 
distinctly at higher rotor speeds (Fig. 1A).  
Application of externally lower punch vibration led to 
comparatively less pronounced decrease of the tensile 
strength (Fig. 1B) and it was possible to manufacture 
tablets with a sufficient tensile strength, even at high 
rotor speeds. The resulting tensile strengths of the tablets 
were obviously directly linked to the physical properties 
of the respective powder blends. 
Fig. 1: Tensile strength of the investigated MCC 
tablet formulations depending on the applied rotor 
speed after conventional tableting (A) and by 
application of lower punch vibration (B) (means ± 
SD, n = 40). 
The capping indices of the investigated MCC 
formulations are displayed in Fig 2. The results of the 
MCC-301 tablets are not shown, because no lamination
occurred. In accordance with the results shown in Fig.
1A, the capping indices increased at higher rotor speeds
during conventional tableting. In comparison, lower
punch vibration was able to decrease the capping index
and thus the lamination tendency to a significant extent
even at high rotor speeds.
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Fig. 2: Capping indices of the investigated MCC 
formulations depending on the applied rotor speed 
and the externally applied lower punch vibration 
(means ± SD, n = 20). 
DISCUSSION 
As shown in Fig. 1A, it was possible to manufacture 
tablets with sufficient tensile strength even at high rotor 
speeds by application of lower punch vibration. The 
applied lower punch vibration probably led to an 
enhanced die filling resulting in a more homogeneously 
and denser powder bed packing within the die. As a 
consequence of this “pre-densification” during the die 
filling process and prior to the main compaction step, the 
number of potential binding points and interparticle 
interactions between the particles increased, which 
ultimately led to an improved mechanical stability of the 
tablets. The lamination tendency was also distinctly 
decreased by the application of lower punch vibration 
(Fig. 2). This observation is attributed to the 
densification step of the powder bed within the die and 
the associated improved removal of entrapped air. The 
volume of entrapped air particularly depends on the 
physical powder properties and on the production 
settings (rotor speed). A low relative density in 
combination with a broad particle size distribution and 
needle shaped particles may increase the volume of 
entrapped air. Hence, a powder blend such as MCC-301 
with a nearly spherical particle shape, a narrow particle 
distribution, a high relative density, and an adequate 
powder flow, showed a higher tensile strength and a less 
pronounced lamination tendency in comparison to 
MCC-102, MCC-12, and MCC-200. Furthermore, the
removal of entrapped air is limited by the adjusted rotor
speed.
CONCLUSIONS 
In the present study, it was shown that the tensile 
strength as well as the lamination tendency of the tablets 
prepared from the investigated powder blends definitely 
depended on the physical properties of each powder 
blend. Moreover, the rotor speed and thus the resulting 
time for filling and compression strongly affected the 
mechanical stability of the prepared tablets. It is 
assumed that the application of external lower punch 
vibration during the die filling step and prior to the main 
compaction step leads to a pronounced increase of the 
tensile strength as well as a decrease of the capping 
index in comparison to conventional tableting. This is 
attributed to the removal of entrapped air and a 
rearrangement of the particles within the powder bed 
inside the die. Thus, external lower punch vibration 
might be a promising approach to improve the 
mechanical stability of tablets and to reduce or prevent 
capping or lamination during or after tablet 
manufacturing 
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ABSTRACT  
Polycyclic polyprenylated acylphloroglucinols (PPAPs) exhibit a broad range of biological activities, such as 
antidepressant, antibacterial, antiviral and antitumor properties. The content of PPAPs in the producing plants is often 
quite low, and their complex structures make total chemical synthesis difficult and economically impractical. Progresses 
in synthetic biology provide an alternative approach for the production of these valuable compounds. Here we present 
our results on reconstruction of the biosynthetic pathways of PPAP precursors in yeast. Based on our previous works on 
the biosynthesis of PPAPs, genes involved in the formation of benzophenones and xanthones from Hypericum sp. and 
other organisms were expressed in yeast either episomally or by integration into the genome. The production of the 
expected products reached around 0.5 mg/l, which is high enough to be the substrate for enzymes of subsequent 
biosynthetic steps. The yeast strains will be further engineered by introducing various prenyltransferase enzymes to 
reconstruct the full biosynthetic pathways of PPAPs. 
Keywords: benzophenone, xanthone, yeast, prenyltransferase, synthetic biology 
INTRODUCTION 
Polycyclic polyprenylated acylphloroglucinols 
(PPAPs) are a group of structurally fascinating and 
synthetically challenging plant secondary products, 
which exhibit a broad range of biological activities, 
such as antidepressant, antibacterial, antiviral and 
antitumor properties [Yang, 2018]. The biosynthesis of 
PPAPs involves both the type III polyketide pathway 
and the terpenoid pathway. The acylphloroglucinol 
cores of PPAPs are produced via a characteristic type 
III polyketide biosynthesis process involving the 
condensation of one acyl-CoA and three malonyl-CoAs 
to form a tetraketide intermediate, which in turn 
cyclizes and aromatizes to yield acylphloroglucinols. 
Prenylation of this core structure and further 
cyclization of the prenyl side chains afford different 
PPAPs with diverse carbon skeletons. The type of acyl 
group, the number and position of isoprenyl residues, 
the degree of oxidation of isoprenyl side chains and the 
corresponding locations of ether rings as well as 
different types of secondary cyclizations (such as aldol, 
Diels−Alder, etc.) create PPAPs’ structural diversity 
and complexity.  
PPAPs have been exclusively isolated from plants of 
the families Hypericaceae and Clusiaceae, mainly from 
the genera Hypericum and Garcinia with only few 
exceptions [Fiesel, 2015]. The content of PPAPs in the 
producing plants is often quite low, and their complex 
structure makes total chemical synthesis very difficult 
and in general economically impractical because of the 
low yield. Recent progresses in synthetic biology 
provide an alternative approach for the production of 
these valuable compounds. For example, artemisinic 
acid, the precursor of the antimalarial drug artemisinin, 
was successfully produced in engineered yeast cells 
with a yield of 25 g/l. Here we present our results of 
reconstruction of the biosynthetic pathways of benzo-
phenone and xanthone in yeast. 
RESEARCH CONCEPT 
Plasmid construction and yeast strains:  HpPKS006 
is a type III polyketide synthase gene cloned from 
Hypericum perforatum, which has both benzophenone 
synthase (BPS) and isobutyrophenone synthase (IBS) 
activities [unpublished]. RpBZL is a benzoyl-CoA 
ligase gene from Rhodopseudomonas palustris 
[Egland, 1995]. HcTXS and HcX6H are xanthone 
synthase and xanthone 6-hydroxylase from H. 
calycinum, respectively [El-Awaad, 2016]. HpPT8 is a 
xanthone prenyltransferase [Fiesel, 2015]. Yeast strains 
used are INVSc1 (Invitrogen), CEN.PK102-5B 
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[Entian, 2007] and DD104, which contains down-
regulation of endogenous farnesyl pyrophosphate 
synthase, ERG20, by site-directed mutation of K197G, 
proven to provide more free IPP/DMAPP and GPP 
[Fischer, 2011, Li, 2015]. Genome intergration was 
carried out using integrative EasyClone vectors with 
auxotrophic selection markers [Jensen, 2014].  
Fig. 1 Schematic illustration of the reconstruction of 
PPAP biosynthetic pathways in yeast. The endogenous 
yeast genes are in green, exogenous genes are in red.  
Reconstruction of benzophenone and xanthone 
biosynthetic pathways in yeast: HpPKS006 and 
RpBZL were subcloned into the vector pESC-URA 
(Agilent Technologies), HcTXS and HcCPR 
(cytochrome P450 reductase gene from H. calycinum) 
were subcloned into the vector pESC-LEU. HcX6H 
and HpPT8 were subcloned into the vector pESC-HIS.  
The promoters of all the pESC vectors were changed to 
the constitutive promoter TEF1-PGK1. 
Different combinations of the constructs were co-
transformed into appropriate yeast strains using a high 
efficiency lithium acetate transformation protocol 
[Gietz, 2007]. The resulting positive yeast clones, after 
being verified by PCR, were cultured in 10 ml of 
synthetic dextrose dropout medium (-Leu, -His, -uracil) 
with D-glucose as the carbon source at 30°C and 200 
rpm shaking for 36 hours. Then, the yeast cells were 
diluted into 20 ml of different media to OD600 0.05 and 
cultured at the same conditions. Benzoic acid was 
added at different time points with a final concentration 
of 3.5 mM. One ml of yeast cultures were taken at 
different time points, extracted twice with the same 
volume of ethyl acetate. Extracts were combined and 
dried under a stream of nitrogen, the residues were 
dissolved in 50% (v/v) methanol for HPLC-DAD 
analysis. The product peaks were collected from HPLC 
and analyzed by LC-MS. The content of target 
compounds in the samples was quantified based on 
calibration curves of authentic references. 
RESULTS 
Selection of culture medium: Among the three 
common yeast culture media, YPD is the best for both 
growth and product formation (Table 1). There are no 
significant differences between episomal expression 
and genome integration of the pathway genes.    
Table 1 Kinetics of growth and benzophenone 









YPD genome 0.389 16.60 12.5 180 
episomal 0.386 13.62 12.8 230 
YPGE genome 0.195 3.24 1.7 60 
episomal 0.190 3.50 1.1 40 
SGI genome 0.290 3.14 0 0 
episomal 0.250 2.80 0 0 
Production of expected compounds: The engineered 
yeast strains produced the expected products at a level 
of 0.1 mg/l without feeding benzoic acid in yeast strain 
INVSc1. Feeding exogenous benzoic acid increased the 
2,4,6-trihydroxybenzophenone yield by a factor of 4 
(Fig. 2). In contrast, yeast strain DD104 produced 
product only without feeding benzoic acid. Adding 
benzoic acid to a final level of 0.15 mM abolished 
product formation completely (data not shown).  
Fig. 2 Feeding benzoic acid increased the production of 
2,4,6-trihydroxybenzophenone in yeast strain INVSc1 
episomally over-expressing HpPKS006 and RpBZL and 
grown in flask cultures.  
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DISCUSSION 
Here we successfully reconstructed the benzophenone 
and xanthone biosynthetic pathway in yeast using 
constitutive promoters, which simplify the production 
procedure by eliminating the induction step. There was 
no significant difference between the episomal 
expression and the genome integration in terms of both 
growth and product formation, indicating that the 
pathways are independent of the copy number of the 
genes. A similar result has also been found in the 
production of resveratrol in engineered yeast [Li, 
2016]. The formation of benzophenone and xanthone 
proceeded by a growth-dependent manner, which has 
also been reported for resveratrol engineering works 
[Vos, 2015].  
Although there is no information about benzoic acid 
metabolism in yeast, the fact that the engineered yeasts 
produce benzophenone and xanthone without feeding 
benzoic acid indicates that endogenous benzoic acid 
exists in yeast. The engineered benzophenone and 
xanthone biosynthesis process in yeast is a de novo 
production system. Further modification of the benzoic 
pathway may be helpful for increasing the product 
yield. 
Co-expressing HpPT8 in the xanthone producing yeast 
strain failed to produce detectable amounts of 
prenylated xanthone, indicating that more optimization 
works are needed to enable the correct function of 
prenyltransferase activity in yeast, as shown previously 
by bitter acid biosynthesis in yeast [Li, 2015]. 
CONCLUSIONS 
Engineered yeast strains produce the core structures of 
PPAPs at yields of around 0.5 mg/l. This amount is 
sufficient to serve as substrate for the downstream 
prenyltransferase enzymes, which have Km values at 
approx. 200 µM. Thus, the strains so far generated can 
serve as the host strains for further reconstructing the 
complete pathways of PPAPs, which then may be 
available in sufficient quantities for the detailed 
assaying of their biological activities.  
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ABSTRACT  
Ion-exchange chromatography (IEC) is the most frequently used technique to purify proteins and therefore, plays an 
important role in process development for therapeutical proteins. To improve the purification using ion-exchange 
chromatography, adequate characterization of adsorption isotherms is obligatory. The Elution by Characteristic Point 
method (ECP) can be used to determine adsorption isotherms applying only minor amounts of sample material to the 
chromatography column. Here, the applicability of the extended ECP method to determine adsorption isotherms of the 
model protein bovine serum albumin (BSA) using bovine hemoglobin (bHb) as tracer substance to quantify all non-
idealities of the system is shown. The resulting isotherm was validated using the static batch approach. In the next step, 
the gained knowledge is used to measure isotherms of Labyrinthopeptins A1 and A2, which show promising activity 
against retroviruses like herpes simplex virus or human immunodeficiency virus. 
Keywords: Adsorption isotherm, Elution by Characteristic Point, Ion-Exchange Chromatography, Labyrinthopeptin 
INTRODUCTION 
The market for biopharmaceuticals is still growing, 
reaching the highest number of new approvals since 
1996 in 2017 [Morrison, 2018]. In the same year sales 
of biopharmaceuticals reached 188 billion US$ with 
monoclonal antibodies alone combining for 65.6% of 
total sales [Morrison, 2018; Walsh, 2018].  
General production schemes for biopharmaceuticals 
consist of the production of the target product using 
mammalian cells or microorganisms and subsequent 
downstream processing. Chromatography is the most 
frequently used technique for the purification of 
biopharmaceuticals. For industrial applications, 45% of 
all chromatographic purification steps are ion-exchange 
chromatography steps [Karlsson, 2011]. This implies 
the important role IEC plays in the production of 
biopharmaceuticals. However, chromatographic 
purification processes are still expensive making 
downstream processing with up to 80% of the overall 
process costs the most cost-intensive part in the 
production of biopharmaceuticals [Roque, 2004]. 
Hence, one should focus on finding efficient and 
therefore economic operation points for a specific 
chromatographic separation task.  
Lanthipeptides, post-translationally modified peptides 
with a characteristic polycyclic structure, are such a 
promising group of biopharmaceuticals showing high 
potential against retroviruses in vitro [Meidl, 2010], but 
with large differences in their potential [Férir, 2013]. 
For example, Labyrinthopeptin A1 is 10-fold more 
potent against herpes simplex virus and human 
immunodeficiency virus than Labyrinthopeptin A2 
making a separation of these peptides desireable.  IEC 
is a very promising separation technique as shown for 
nisin, another prominent lanthipeptide [Abts, 2010]. 
A deep understanding of the interaction between 
peptides and stationary phase under various process 
conditions is needed to account for variations in the 
fermentation broth fed into the downstream processing. 
Hence, the characterization of adsorption isotherms is 
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essential for process development. While a variety of 
methods has been described in literature to determine 
adsorption isotherms experimentally, only the dynamic 
so-called Elution by Characteristic Point (ECP) method 
offers the possibility to gain complete isotherm data 
with just one experiment leading to smallest 
consumption of substance [Seidel-Morgenstern, 2004]. 
This low demand is a crucial advantage as the targeted 
peptides A1 and A2 are not commercially available but 
have to be produced and purified specifically for 
adsorption experiments. One of the most limiting 
factors for ECP, especially in early stage development, 
is the need for a high number of theoretical stages to 
provide accurate isotherm data. This limitation was 
recently overcome by an Extended Elution by 
Characteristic Point (EECP) method, where non-
idealities of the system, e.g., convection, dispersion or 
low number of theoretical plates are quantified by 
using a specific marker substance [Hartig 2015]. 
In this work, EECP is transferred to the system of 
labyrinthopeptins and ion-exchange resins. To this end, 
the cheap and easy available proteins BSA and bHb are 
used as model substances to characterize the required 
process conditions to generate adsorption isotherms 
and to understand occurring problems and limitations. 
Then, the knowledge is used to measure adsorption 
isotherms of labyrinthopeptins on ion-exchange resins. 
THEORY 
This section gives a brief summary of the derivation 
and use of EECP [Hartig, 2015]. The standard 
equilibrium model of chromatography neglects 
dispersion and assumes instantaneous adsorption 
equilibrium between the bulk fluid phase and the 
particle at every axial position. While the equilibrium 
assumption can be fulfilled by using low flow rates and 
small particle diameters, neglecting the axial dispersion 
leads to the need of a high number of theoretical plates 
in classical ECP. In contrast, EECP method assumes 
that all non-idealities, e.g., non-rectangular injection 
profile and axial dispersion, are linearly independent 
from the effects of adsorption and can be determined 
by a tracer injection. Hence, all non-ideal influences 
are lumped into a concentration-dependent system dead 
volume VS that is subtracted from the retention volume 
of the adsorptive VR. Then, the loading is calculated 
using this corrected retention volume (VR – VS): 








It is worth stressing that 𝑐° and 𝑐° represent the 
normalized concentrations of the adsorbing and the 
tracer substance, respectively. Both concentration 
profiles are normalized for comparability.  
RESULTS AND DISCUSSION 
As discussed in the last section, the application of 
EECP requires the flow rate to be small enough to 
allow for an establishment of equilibrium between bulk 
liquid and stationary phase. Hence, Fig. 1 shows the 
influence of the superficial velocity on the determined 
Henry coefficient for BSA vs bHb defined by: 
𝐻 (3)
The superficial velocity was corrected for a decreased 
available cross section due to partial blocking of the 
bed as determined by total porosity measurements 
using glucose as tracer (see [Hartig, 2017] for further 
details on porosity measurement). It becomes obvious 
that the superficial velocity should not exceed 
10 mm/min to allow neglecting kinetic effects. 















Corrected superficial velocity [mm∙min-1]
Range from Batch experiments
Figure 1: Henry coefficient between BSA and bHb on 
Q Sepharose FF at 25 °C in 20 mM sodium phosphate buffer 
(ph 7) determined by retention time of peak maximum at 
varying superficial velocity. Concentration of BSA and bHb 
was approximately 7 µM and 10 µM, respectively. 
Volumetric flow was varied between 25 µL/min and 
400 µL/min. Data from [Hartig, 2017]. 
Besides the use of a feasible small flow rate, two 
additional factors had to be included to determine BSA 
isotherms. First, only 35% of the expected total 
porosity were measured leading to a correction of the 
mass of adsorbent to only 35% of the mass weighted 
into the column. Second, bHb showed a measureable 
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adsorption at the applied conditions. Hence, the slope 
of the bHb isotherm was determined in batch 
experiments (data not shown) and this slope was added 
to the BSA isotherm. With these corrections, the 
adsorption isotherms of BSA were determined. This is 
exemplary shown at 25 °C in Fig. 2.  



















 BSA 25 °C EECP
 68% Confidence interval EECP
 BSA 21 °C Batch
Figure 2: Adsorption isotherm of BSA at 25 °C in 20 mM 
sodium phosphate buffer (ph 7), bHb was used as tracer. 
Data from [Hartig, 2017]. 
A good agreement between the results of batch and 
EECP measurements can be seen. Size exclusion 
effects that could not be totally ruled out due to the 
different shape of BSA and bHb might cause the small 
deviation at higher concentrations. This stresses the 
importance to find feasible tracers for the particular 
adsorptive. With respect to used material, static 
adsorption experiments needed about 37 mg BSA 
whereas one EECP isotherm was measured with only 
12 mg BSA. Although the calibration of the detector 
and the determination of a feasible flow rate lead to an 
additional consumption of about 25 mg BSA, 
recalibration is not necessary for the investigation of 
other conditions like different buffer concentrations or 
temperatures. Overall, EECP might reduce the material 
needed by nearly 70% for all further isotherms 
compared to batch. 
The behavior of the small peptides Labyrinthopeptin 
A1 and A2, having molecular masses of 2.072 kDa and 
1.922 kDa, respectively, might differ notably from the 
larger protein BSA (66.5 kDa) due to increased 
diffusion coefficient but also increased diffusion path 
inside the porous matrix. Hence, adjustment of the 
experimental conditions is mandatory to fulfill the 
equilibrium assumption before conducting EECP 
measurements. As indicated in Fig. 3, superficial 
velocities below 10 mm/min should be chosen for 
Labyrinthopeptin A1 to ensure establishment of 
equilibrium. It is worth noting that the similar value 
compared to BSA should rather be seen as coincidence 
since the impact of smaller molecule size on diffusion 
kinetic is complex. The retention coefficient can be 
calculated using the retention volume at the peak 
maximum: 
𝑘  (4)













Figure 3: Retention coefficient of Labyrinthopeptin A1 on 
Q Sepharose FF at 25 °C in 20 mM Bis-Tris buffer (ph 7) 
with 200 mM sodium chloride at varying superficial 
velocities. 
CONCLUSION AND OUTLOOK 
The extended Elution by Characteristic Point method is 
a rapid approach to determine adsorption isotherms 
consuming only small amounts of sample material. 
This was successfully shown for model proteins BSA 
and bHb on Q Sepharose FF, where a good correlation 
to the well-established batch method can be seen. 
Since the method has been established for the model 
proteins BSA and bHb and crucial process parameters 
for the determination of adsorption isotherms for 
labyrinthopeptins on Q Sepharose FF have been 
characterized, isotherm data for A1 and A2 will be 
generated in future experiments. 
NOMENCLATURE 
c concentration, mg/L 
k’ retention coefficient, 1 
m mass, mg 
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q loading of adsorbent, mg/mg 
V volume, mL 
BSA bovine serum albumin 
bHb bovine hemoglobin 
ECP elution by characteristic point 
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ABSTRACT  
The rapid development of affordable medications relies on the knowledge of suitable solvents for potential active 
pharmaceutical ingredients. Molecular simulations can be interpreted as computational experiments and may complement 
laboratory experiments, as they not only enable the calculation of thermophysical properties but also allow for an insight 
into a systems behavior on the molecular level. Relative solubilities can be predicted by using molecular simulations to 
calculate the Gibbs free energy of solvation ΔGsolv. We developed algorithms to reduce the required computational effort 
and increase the statistical precision by improved alchemical pathways. However, the agreement between ΔGsolv 
predictions from simulations and experimental data depends on the molecular models (force fields) used. To consider 
polarization effects, we combined partial charges derived by the IPolQ-Mod method with the General Amber Force Field 
(GAFF) and found a comparable ΔGsolv accuracy to GAFF and its default RESP charges for a large set of compounds in 
various solvents. We initiated a parameter optimization to improve the accuracy of GAFF/IPolQ-Mod and present our 
current results of the refitting process. 
Keywords: Molecular simulation, solvation free energy, force field optimization 
INTRODUCTION 
Molecular simulations, e.g. with the Gromacs (Abraham 
et al. 2015) software, can complement laboratory 
experiments, as they not only allow for the calculation 
of thermophysical properties but also for the qualitative 
assessment of a systems behavior on the molecular level. 
A property of special interest is the Gibbs free energy of 
solvation ΔGsolv, which is fundamental for the 
calculation of e.g. relative solubilities, partition 
coefficients or activity coefficients. ΔGsolv characterizes 
the isothermal isobaric change of states of a solute 
molecule that transitions from a vacuum into a 
condensed phase. The corresponding change in free 
energy describes the strength of the solute/solvent 
interactions as well as the impact of entropic effects. For 
accurate free energy results, the thermodynamic end 
states, i.e. solute in vacuum and solvent phase 
respectively, need to exhibit sufficient configurational 
space overlap. In practice, a linking chain of 
intermediate states with scaled solute/solvent 
interactions, the so called alchemical pathway, is 
constructed. It allows for overlap between neighboring 
states and partial free energy results are summed for the 
total outcome. However, while a large number of 
intermediates enables good overlap and high statistical 
precision, the required computational effort increases 
with the number of intermediates. 
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On the other hand, ΔGsolv results strongly depend on the 
molecular models (so called force fields) applied. 
Widely used force fields (Wang et al. 2004; 
Vanommeslaeghe et al. 2010; Jorgensen et al. 1996) for 
the description of drug-like molecules assign fixed 
partial charges to the atomic sites. Consequently, these 
force fields are not capable to consider important 
polarization effects. For an at least implicit 
representation of polarization effects, we combined the 
IPolQ-Mod (Muddana et al. 2014) partial charge 
calculation method with the General Amber Force Field 
(GAFF) (Wang et al. 2004) and compared the ΔGsolv 
results to those obtained with GAFF but with the default 
RESP (Bayly et al. 1993) charge calculation method. In 
a previous study (Mecklenfeld und Raabe 2017a), we 
found comparable agreement between results with 
GAFF/RESP and GAFF/IPolQ-Mod to experimental 
data and concluded that GAFF/IPolQ-Mod is a suitable 
basis for the application of the physically motivated 
IPolQ-Mod method. However, as the alteration of the 
charge calculation method perturbs the self-consistency 
of the GAFF model, we also proposed the optimization 
of relevant atom types in various chemical environments 
in order to improve the ΔGsolv predictions. 
RESEARCH CONCEPT 
OPTIMIZATION OF THE NUMBER AND 
DISTRIBUTION OF INTERMEDIATES STATES 
Fig. 1. Curve progression of normalized cumulated 
partial uncertainties with regard to λ. At the end of the λ 
state optimization, the objective of equal partial 
uncertainties, represented by equidistantly spaced cuts 
with the ordinate axis (blue lines), is well meet.  
Intermediates states are characterized by λ-scaled 
solute/solvent interactions, whereas λ=0 equals no 
solute/solvent interactions (solute in vacuum) and λ=1 
corresponds to full interactions in the condensed phase. 
By defining a vector of λ values between 0 and 1, 
configurational space overlap can be established. The 
solvation free energy difference is thereby split into 
partial results ΔGsolv,i,i+1 between states λi and λi+1, which 
are summed for the total outcome. A priori, a suitable 
number or distribution of λ states is unknown and thus 
sufficient configurational space overlap is often 
accomplished by using a large number of intermediates.  
As each partial result ΔGsolv,i,i+1 contributes to ΔGsolv, our 
optimization goal is to ensure even partial uncertainties 
δΔGsolv,i,i+1 for improved statistical precision of the 
overall ΔGsolv result. We developed algorithms that 
allow for the adaptation of the number and distribution 
of the intermediates by a series of short trial simulations 
(Mecklenfeld und Raabe 2017b). As illustrated in Figure 
1, cumulated partial uncertainties are interpreted as a 
function of λ. Using interpolation, new λ states can be 
defined to ensure the same level of statistical precision 
for all intermediate results. The configurational space 
overlap is analyzed after each of the short simulations 
and empirically derived algorithms adapt the number of 
intermediates if the overlap is considered to be 
insufficient or too excessive. After the number and 
distribution of intermediates converged, the actual 
production phase is initiated.  
CALCULATION OF PARTIAL CHARGES 
The IPolQ method is an abbreviation for “Implictly 
Polarized Charges” and was proposed by Cerutti et al. 
(Cerutti et al. 2013). The approach was later simplified 
by Muddana et al. and named IPolQ-Mod accordingly. 
Using ab initio calculations in Gaussian (Frisch et al. 
2009), molecule geometries are optimized at the  
HF/6-31G* level of theory. Partial charges for the solute 
molecule are calculated both in the vacuum and 
condensed phase at the MP2/aug-cc-pVDZ level of 
theory and charges from both phases are then averaged. 
For the description of charges in the solvent, the PCM 
model by Mennucci et al. (Mennucci et al. 1998) is 
employed. For default GAFF charges, the HF/6-31G* 
level is applied. All partial charges are derived by a two-
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OPTIMIZATION OF ATOM TYPES 
For the optimization of Lennard-Jones parameters εii and 
σii for relevant atom types, we employed the robust 
Nelder-Mead (Nelder und Mead 1965) algorithm and 
use an objective function that considers weighted 
normalized root mean square deviations for solvation 
free energies and densities of the pure compounds. To 
reduce the computational effort, we utilize a 
thermodynamic cycle for the parameter optimization 
process. The training data set includes 358 solvation free 
energy results and 286 densities in a broad temperature 
range for a multitude of model compounds and chemical 
environments to account for prominent functional 
groups in potential drug candidates.  
RESULTS AND DISCUSSION 
In Figure 2, solvation free energies from GAFF/RESP 
and GAFF/IPolQ-Mod are plotted versus the 
corresponding experimental data. The figure 
demonstrates comparable accuracies for the different 
charge calculation methods, though specific outliers 
exists for both.  
Fig. 2. Solvation free energy results from GAFF/RESP 
and GAFF/IPolQ-Mod over experimental data. 
Simulation results for the ongoing optimization of atom 
types (ch2, ch3, ca, oh, ohP, os and cl already 
considered) are depicted in Figure 3. The figure 
highlights the improved agreement between ΔGsolv 
results using GAFF/IPolQ-Mod + LJ-refit and 
experimental data compared to the GAFF/RESP and 
GAFF/IPolQ-Mod models.  
Fig. 3. Solvation free energy results from GAFF/RESP, 
GAFF/IPolQ-Mod and GAFF/IPolQ-Mod with refitted 
Lennard-Jones parameters over experimental data. 
CONCLUSIONS 
Molecular simulations are capable to complement 
laboratory experiments. The precise prediction of 
solvation free energies for the estimation of relative 
solubilities requires sufficient configurational space 
overlap for the ΔGsolv results to converge, and accurate 
molecular models for the description of the molecule 
interactions. We have developed methods to ensure 
statistical precise free energy results with reduced 
computational effort, and studied the impact of IPolQ-
Mod partial charges for an implicit representation of 
polarization effects on the GAFF model compared to the 
default force field charges. 
Though IPolQ-Mod adds physical details to the model, 
the charge scheme perturbs the self-consistency of the 
force field. We therefore optimize Lennard-Jones 
parameters of GAFF atom types for IPolQ-Mod partial 
charges, and our results demonstrate significantly 
improved agreement with experimental data. 
Suitable molecular models for exact predictions of 
solvation free energies and linked thermophysical 
properties may improve the understanding of solubility 
processes in order to reduce the effort for the 



















































RMSD in kJ/mol 
GAFF/RESP 4.57 
GAFF/IPolQ-Mod 5.37 




+ LJ-refit 1.89 
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ABSTRACT  
Novel Polymerized Ionic Liquids (PILs)-based Hydrogels as Innovative Drug Delivery Systems are presented. The 
embedding of drugs in hydrogels enables the “smart” delivery of bioactive molecules from drugs for an oral route of 
administration. Therefore, a high mechanical strength as well as a favorable pH-dependent swelling behavior is required 
which is shown in this study. A mechanical compression of PILs-based hydrogels up to 98.5% and a high swelling 
behavior of poly(VEImBr) hydrogels in a solution with a high pH value is achieved. A significant lower swelling is 
achieved in a solution with a lower pH value. 
Keywords: Hydrogel, Polymerized Ionic Liquids, Drug Delivery 
INTRODUCTION 
Due to the growing demand for a controlled release of 
drugs in the pharmaceutical industry, there has been a 
considerable interest in the development of novel and 
reliable drug-delivery systems. Therefore, the literature 
considers various approaches, including the embedding 
of drugs in hydrogels. Such innovative systems enable 
the “smart” delivery of bioactive molecules from drugs. 
However, there are several disadvantages of already 
existing intelligent hydrogels, such as their low 
mechanical stability, limited and not completely 
reversible swelling capacity, and slow response to 
external stimuli. Due to the inadequate properties of 
these existing hydrogels our focus is on novel 
polymerized ionic liquids-based hydrogels as drug 
carriers for oral route of administration. The aim of this 
research is to achieve a selective drug release from 
hydrogels over a defined time period and at a specific 
location in order to control the duration of the action 
while minimizing undesired effects outside the site of 
action.  
RESEARCH CONCEPT 
In order to investigate the PILs-based hydrogels as 
innovative drug delivery systems, the dimensionally-
stable PILs are being obtained by radical 
polymerization. An imidazolium-based ionic liquid 
bearing a vinyl group is polymerized with the cross-
linker N,N’-methylenebisacrylamide. The embedding of 
a drug can be achieved by adding an active 
pharmaceutical ingredient (API) dissolved in water 
during the synthesis, as shown in Figure 2. As model 
substances simplified structures of protein kinase 
inhibitors are used. There are several variation 
possibilities during the synthesis, which have decisive 
effect on the synthesis of the 
hydrogel, e.g. content and type 
of cross-linker, water content 
and the ionic liquid. At the 
same time, however, the 
properties of the hydrogel is 
obviously also influenced by 
the variation. 
Figure 1. Synthesized
Hydrogels in a fresh
(left) and dried (right)
state. 
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Figure 2: Synthesis of PILs-based hydrogel poly(VEImBr); 
radical polymerization of [VEIm] [Br] – 1-Vinyl-3-
ethylimidazolium bromide and cross-linker N,N’-
methylenebisacrylamide. APS – Ammonium peroxydisulfate, 




Due to their high water content hydrogels possess 
generally a weak mechanical strength. However, the 
advantage of PILs-based hydrogels over e.g. alginate-
based hydrogels is their significantly higher mechanical 
stability [Bandomir, 2014]. The mechanical properties 
are affected by the IL monomer, composition, cross-
linking density, degree of drying or swelling and drying 
method. A reversible compressibility (ε) of a fresh 
synthesized poly(VEImBr) hydrogel in physiological 
saline of up to 72% without crack formation is achieved. 
This compression behavior is increased by increasing 
the drying time in a climatic chamber.  

























 poly(VEImBr) in NaCl solution
 poly(ViPrImBr) in NaCl solution
Figure 3: Elongation tests of poly(VEImBr) and 
poly(ViPrImBr) hydrogels with different degrees of drying at 
25 °C and 60% RH partially in 0.9% NaCl solution with a 
loading speed of 0.1%/s. 
With increased drying time, the reversible compression 
without crack formation increased already up to 98.5% 
in the air and up to 88.9% in physiological saline for 
poly(VEImBr), for poly(ViPrImBr) up to 87.4%, as 
shown in Figure 3. 
Swelling behavior 
The swelling property of hydrogels is a significant factor 
for controlled drug releases [Rizwan, 2017]. Drug 
release generally involves the simultaneous absorption 
of water and desorption of a drug via a swelling-
controlled diffusion mechanism. The produced 
hydrogels show a pH-dependent swelling behavior, as 
shown in Figure 4Fehler! Verweisquelle konnte nicht 
gefunden werden.. Due to the large variations of pH-
values at various body sites, the swelling and thus the 
release of the API will only take place at the desired site 
of action in the body. By further functionalization of the 
PILs, the swelling behavior of the hydrogels as well as 
the drug release can be affected crucial. 



























Figure 4: Swelling trend of fresh poly(VEImBr) hydrogels in 
0.9% NaCl solution with different pH-values. 
Drug release behavior 
Initial findings on the drug release behavior can be 
adapted from catalyst-leaching experiments 
[Großeheilmann, 2015]. Leaching behavior with 
different drying methods, catalyst structures, water 
content, and solvents was investigated. Due to these 
experiments, drug release mechanisms can be 
influenced by various parameters, such as drying 
methods, crosslinker-to-IL ratio, IL monomer, solvent / 
pH of the aqueous medium, drug size, and drug polarity. 
The first studies on drug release behavior of model 
substances are currently under investigation. As model 
substances simplified structures of protein kinase 
inhibitors, which are used in the development of drugs 
for Down syndrome and Alzheimer’s disease, are used.  
Biocompatibility 
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Initial experiments show that most of the IL monomers 
are toxic before polymerization, except monomers with 
an isopropyl group. Fortunately, the PILs-based 
hydrogels show low to no toxicity after polymerization. 
Further biocompatibility tests are currently under 
investigation. In addition, the change from a batch 
process to a continuous process for washing out 
unreacted IL monomer from the PILs is currently being 
developed to obtain biocompatible PILs-based 
hydrogels. 
CONCLUSIONS 
Stable PILs-based hydrogels were successfully 
synthesized by a radical polymerization. The 
mechanical stability of these hydrogels is shown by a 
reversible compression up to 90% without crack 
formation. Initial findings show low to no toxicity after 
polymerization. Drug release can be controlled by pH-
dependent swelling behavior. In future, an increased pH-
responsive drug release should be obtained by 
functionalizing the PILs. 
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NOMENCLATURE 
API Active Pharmaceutical Ingredient 
APS Ammonium peroxydisulfate 
IL Ionic Liquid 
PILs Polymerized Ionic Liquids 
RH Relative Humidity 
TEMED N,N,N’,N’-Tetramethylethane-1,2-
diamine 
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ABSTRACT  
Tablets are the most common dosage form in the pharmaceutical industry. Rapid drug release is ensured by quick tablet 
disintegration which is caused by the absorption of water into the tablet. Therefore, water uptake and subsequent volume 
expansion are necessary requirements for tablet disintegration. In this work, binary mixtures of excipients were compacted 
to tablets with varying structural and mechanical properties to determine the influence of formulation and process 
parameters on water uptake and resulting swelling force of tablets. Results showed strong influences of disintegrant 
concentration as well as tablet porosity on both absorbed amount of water and acting swelling force. Obtained results 
revealed that water uptake and swelling force measurements are useful tools for an improved understanding of tablet 
disintegration. 
Keywords: Water uptake, swelling force, tablets, disintegrants 
INTRODUCTION 
The majority of commercial tablets are designed to 
release at least parts of their active pharmaceutical 
ingredient (API) immediately after administration. The 
API release is directly depending on the available 
surface area which can be greatly enhanced by rapid 
tablet disintegration. Therefore, disintegrants are added 
to tablet formulations ensuring the quick disintegration 
of tablets into smaller fragments. The intrusion of water 
into the tablet is a necessary requirement for 
disintegration to occur. The absorbed water mitigates 
interparticulate bonds and therefore, results in a 
deteriorated mechanical tablet strength. The disruption 
of the tablet matrix can be further accelerated by 
incorporated disintegrant particles which tend to swell 
up to a multiple of their initial volume. 
For commercial products, the disintegration behavior of 
tablets is solely described by determining the 
disintegration time with a disintegration tester according 
to the applicable pharmacopeia. However, the derived 
disintegration time lacks any insight into processes 
involved during the tablet disintegration and gives no 
information about the course of the tablet disintegration. 
Therefore, custom-built apparatuses to describe acting 
subprocesses, namely water uptake rate and swelling 
force, were built by different authors to characterize the 
interaction of pharmaceutical tablets with water during 
disintegration [Caramella et al., 1988; Catellani et al., 
1989]. The applied methods showed useful insight to 
gain an improved understanding of tablet disintegration. 
However, previously applied studies lack systematic 
investigations of the influence of formulation and 
process parameters as well as physical interpretation of 
derived data. 
RESEARCH CONCEPT 
Applied materials comprised microcrystalline cellulose 
(MCC; Vivapur 102, JRS Pharma) as filler/binder and 
both croscarmellose sodium (Primellose, DFE Pharma) 
and crospovidone (Polyplasdone XL, Ashland) as 
disintegrants. 
Tableting 
Binary mixtures of MCC and disintegrants with varying 
shares of disintegrants (0 – 20 wt.%) were compacted 
into tablets of 450 mg using the compaction simulator 
Styl’One evolution (Medel’Pharm, France). Tablets 
were compacted applying different levels of compaction 
pressures (25 – 400 MPa) using biplanar, round 
11.28 mm Euro-D tooling.  
Tablet analysis 
Tablet porosities were calculated using the geometrical 
measures and mass of produced tablets. Diametrical 
compression strength was measured and tablet tensile 
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strength was subsequently calculated applying the 
equation of [Fell and Newton, 1970]. 
Water uptake and swelling force 
Water uptake of tablets was measured using a 
tensiometer K20 (Krüss GmbH, Germany) with a 
customized setup until derived mass increase undercut 
0.1 mN/s. 
Swelling force of tablets was measured using material 
testing machine zwickiline Z2.5 (Zwick/Roell GmbH & 
Co. KG, Germany). Tablets were placed on metal petri 
dishes and fixed by applying 0.5 N with a steel punch 
acting as a force transmission element. 40 mL of 
distilled water were added and the axial swelling force 
was measured until a decrease of swelling force was 
detected. 
RESULTS & DISCUSSION 
Measured maximal water uptake revealed the ability of 
tablets to absorb a multiple of their own weight 
(Figure 1). Water uptake rises with increasing 
crospovidone concentration possibly due to the 
increased water absorption of disintegrant particles and 
increased disruption of tablet matrix allowing enhanced 
storage of water. Results revealed a considerable 
influence of the densification status of tablets as 
expressed by different water uptake masses for different 
compaction stresses. 



























Figure 1: Water uptake of tablets of MCC + crospovidone for 
different levels of compaction stress and crospovidone 
In contrast, swelling force decreases with increasing 
concentration of crospovidone (Figure 2) most likely 
caused by the rapid disruption and radial relaxation of 
the tablet matrix. Swelling force is found to depend on 
both formulation and process parameters and can exhibit 
considerably high values up to 600 N. 
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Figure 2: Swelling force of tablets of MCC + crospovidone for 
different disintegrant concentrations and tablet porosities 
When correlated with the measured disintegration time, 
swelling force rate was found to be a better indicator for 
rapid tablet disintegration than the maximum values of 
the swelling force due to the rapid disintegration of the 
tablet matrix (data not shown).  
CONCLUSIONS 
Results showed a complex interplay of process 
parameters and formulation on both water uptake and 
swelling force. Applied methods revealed interesting 
insight into acting subprocesses during disintegration. 
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ABSTRACT 
A high pressure and high temperature continuous flow reactor has been used to intensify a Krapcho dealkoxy-
carbonylation reaction in the context of API synthesis. The reactor enables operation of the reaction above temperatures 
possible in batch and thus significantly increased conversion rates are achieved. Also a broader choice of solvents is 
possible by the use of the continuous process. Batch and continuous reaction are compared in terms of operation range 
and space-time-yield. Despite lower concentrations of the reactants in the continuous process, space-time-yield exceeds 
that of the batch process by more than an order of magnitude due to the higher reaction rates.    
Keywords: Flow synthesis, process intensification, Krapcho dealkoxycarbonylation 
INTRODUCTION 
The method of Krapcho is a simple procedure for the 
selective dealkoxycarbonylation of molecules under 
neutral conditions [1,2]. It involves heating of the 
respective reactant molecule in an aprotic polar solvent 
with added water and sometimes salts. At ambient 
pressure, the choice of solvent is limited to high boiling 
polar aprotic solvents such as DMF and DMSO due to 
the demanding temperatures. Figure 1 displays reaction 
temperature and time for several Krapcho reactions 
reported in literature [3,4]. 






























Figure 1: Overview over reaction conditions for different 
Krapcho reactions reported in literature, ntotal = 364 [3,4] 
Obviously, the majority of these reactions only 
progresses at temperatures well above 140 °C, still 
requiring reaction times of several hours. In order to 
intensify the reaction beyond the original batch protocol, 
a continuous high pressure and high temperature flow 
reactor is utilized to access reaction temperature 
windows not possible in batch. By pressurizing the 
reactor, also alternative low boiling solvents could be 
employed, benefiting from their high volatility for easier 
workup. The continuous reactor is tested for a typical 
Krapcho reaction with pharmaceutical relevance, 
namely the synthesis of 3,4-dihydro-1H-1-benzazepine-
2,5-dione (DHBD [5], Figure 2. DHBD and its 
derivatives are important precursor molecules for the 
synthesis of substituted paullones and paullone 
derivatives, a class of protein kinase inhibitors and anti-
cancer agents [6–8]. 
Figure 2: Krapcho dealkoxycarbonylation for the synthesis 
of DHBD in batch mode 
RESEARCH CONCEPT 
In order to examine the reaction in detail, a continuous 
high pressure and high temperature flow reactor has 
been designed and characterized [9]. 
As shown in Figure 3, the center piece of the setup is a 
stainless steel coil reactor with dimensions di x L = 1.016 
x 2,500 mm, VR = 2.027 mL, which is submerged in and 
heated by an oil bath. The reactor is fed by a HPLC 
pump and kept at a constant pressure of 37.5 bar to 
prevent boiling of the solvent. At a given flow rate, 
500 µL of the reactant solution are loaded in the sample 


















Sample loop 0.5 mL
R in solvent / water
Figure 3: Setup of the continuous flow reactor used to study 
the Krapcho reaction 
The reactor outlet stream is collected and analyzed via 
HPLC. In order to generate conversion-time-profiles 
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this procedure is repeated for various combinations of 
temperature (160 – 200 °C) and flow rate (0.1 – 2 mL 
min-1). For comparison batch reactions are performed in 
a Mettler Toledo EasyMax 102 synthesis workstation. 
Kinetic analysis 
The conversion-time-profile of the reactant XR can be 
described by a pseudo 1st order kinetic equation, where 
tR is the residence time of sample fluid element in the 
heated zone of the continuous reactor [10]: 
𝑋𝑅 = 1 − 𝑒𝑥𝑝(−𝑘 ∙ 𝑡𝑅)    (1) 
Since residence time distribution in the coil reactor is 
found to closely follow plug flow behavior [9], 
residence time tR is calculated via reactor volume VR and 
volumetric flow rate ?̇?, corrected by the expansion of






   (2) 
By fitting equation (1) to experimentally determined 
conversion-over-time data, rate constants k can be 
determined. By employing Arrhenius´ law, activation 
energy EA and frequency factor k0 may be calculated: 
𝑘(𝑇) = 𝑘0 ∙ 𝑒𝑥𝑝(−𝐸𝐴 (𝑅 · 𝑇)⁄ )    (3) 
Combination of equations (1) – (3) results in an 
expression for the conversion in the continuous reactor 
as function of temperature and flow rate [9]: 








]   (4) 
RESULTS AND DISCUSSION 
Reaction characterization 
Since water is added as reactant, the influence of its 
concentration on reaction rate was examined.  







 DMSO - 5 mg/mL
 THF - 5 mg/mL
 DMSO - 20 mg/mL
















Reactant ratio  /  molH2O mol-1R
Solvent: THF, DMSO
Temp.: 170 °C
Figure 4: Influence of the ratio of water and reactant on the 
rate of the dealkoxycarbonylation 
Figure 4 displays reaction rate constants for different 
ratios of added water to reactant concentration at varied 
reactant concentrations in solvents DMSO and THF. In 
general, rate constants increase with the amount of water 
added per reactant, until a maximum k-value is reached 
at a ratio of about 10. This behavior can be observed for 
different reactant concentrations ranging from 5 to 50 
mg mL-1 in DMSO.  
For no added water, the reaction still takes place. This 
might be due to the hygroscopic nature of DMSO, which 
always contains small amounts of water. For low ratios 
of added water to reactant concentration, error bars are 
significantly larger, indicating a lower accuracy of the 
used 1st order fit. In this regime, the reaction behaves 
more like a 2nd order reaction where water concentration 
becomes limiting. For THF as solvent, a similar 
behavior is observed, however, the maximum value of k 
is significantly lower than that observed in DMSO.  









 conti., 145 °C
 conti., 160 °C
 conti., 170 °C
 conti., 185 °C
 conti., 200 °C
 batch, 135 °C
 batch, 145 °C














Reaction time  /  s
extrapolation 
of the model
Figure 5: Conversion profiles at different temperatures in 
DMSO in batch and continuous mode [9]  
Figure 5 displays typical conversion-time profiles of R 
to DHBD in DMSO for different temperatures in the 
batch and continuous reactor. Conversion profiles were 
also modeled using equation (4) and batch data to fit the 
parameters. Dotted curves represent extrapolations of 
that model to higher temperatures, with parameters 
extracted from reactions ≤ 160 °C.  
Batch and continuous conversions are in very good 
agreement, however, the reaction temperature in batch 
is limited. Employing the continuous reactor, tempera-
tures of up to 200 °C can be realized resulting in a 
significantly intensified reaction. Consequently, shorter 
reaction times are sufficient to reach complete 
conversion (~ 3 min vs. ~ 3 h respectively).  
Solvent selection 
To identify an optimal solvent for the Krapcho reaction, 
different solvents have been examined as reaction 
medium. Figure 6 summarizes the derived rate constants 
at different temperatures. Whilst aprotic-polar solvents 
show significant reaction rates, ethanol and i-propanol 
are not suited as reaction medium. Here, the equilibrium 
between the reactant and a carboxylate intermediate 
might be affected negatively. Considering aprotic-polar 
solvents, rate constants do not differ dramatically. 
However, DMSO and acetone show the highest rate 
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constants while values of propylene carbonate (PC) and 









































Figure 6: Reaction rate constants k in different solvents 
Besides reaction rate, reactant solubility in the 
respective solvent is an important property. Solubility 
curves of R in different solvents, measured via HPLC 
from a saturated solution, for n ≥ 3 samples each, are 
given in Figure 7. Only DMSO, DMF and DMAc 
exhibit high solubility for the reactant R while acetone, 
PC, EA and ACN show unsatisfactory solubility 
especially at room temperature. Taking a combined look 
at reaction rate and solubility, it becomes apparent that 
DMSO, DMAc and DMF are the most promising 
solvent candidates, since they show both, relatively high 
rate constants and good solubility. THF is the best of the 
low boiling solvents. While the solubility for the 
reactant is not as high as in DMSO for example, it still 
exceeds the other low boiling solvents by a factor ~ 3.   










































Figure 7: Solubility curves of the reactant R in different 
aprotic-polar solvents, n ≥ 3 
Comparison of batch and continuous process 
To assess the process modes, it is interesting to consider 
the operation range of the respective process and 
compare the space-time-yield (STY) as a measure of 
process performance. 
Operation ranges, given in Figure 8, can be interpreted 
as follows: In the batch process, solubility is not an issue 
since dissolution of the reactant can take place during 
heating of the mixture and at reaction temperature, 
solubility is high anyway. In contrast, in continuous 
mode, the reactant has to be dissolved prior to pumping 
to prevent reactor clogging and pump damage by un-
dissolved solids, so reactant concentration is limited. In 
the batch process reaction temperature is limited by the 
boiling temperature of the reaction mixture. Since water 
is added proportional to the reactant concentration, 
maximum possible reaction temperature is decreasing 
with increasing reactant concentration (see Figure 8). In 
the pressurized continuous reactor, this is not an issue 
and higher reaction temperatures can be reached. 





















Reactant concentration  /  mg mL-1
 DMSO - batch
 DMAc - batch
 DMF - batch
 DMSO - conti
 DMAc - conti
 DMF - conti







Figure 8: Operation range of the batch and the continuous 
process 
To quantitatively the influence of reaction temperature 
and concentration on the performance of both processes, 
STY is theoretically assessed as follows: For the batch, 
STY depends on the chosen reactant concentration cR and 
the resulting processing time tproc which is a function of 
the reaction temperature und ultimately of the reactant 




∙ 𝑀𝐷𝐻𝐵𝐷 𝑀𝑅⁄    (5) 
For the continuous process, STY follows from the 
maximum solubility of the reactant SR and the 
volumetric flow rate necessary to provide a sufficient 
reaction time for a conversion of 99.9 %: 
𝑆𝑇𝑌𝑐 = 𝑆𝑅(𝑇𝑆) ∙
?̇?𝑋=99.9% (𝑇𝑅)
𝑉𝑅
∙ 𝑀𝐷𝐻𝐵𝐷 𝑀𝑅⁄    (6) 
The calculated STY are displayed in Figure 9, where 
values for batch represent the highest STY possible at the 
optimum reactant concentration and temperature while 
the values for the continuous process are calculated for 
dissolution temperature TS = 25 °C and reaction 
temperature TR = 200 °C. 
It can be concluded that the STY possible in the batch 
process is about an order of magnitude smaller than in 
the continuous process for the high boiling solvents. 
This can be contributed to the low temperatures and 
therefore slow reaction in batch. This effect can be seen 
especially for THF where the low boiling point would 
lead to reaction times of several years. Although reactant 
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concentration is higher in the batch process, this 
advantage does not balance out the slow rates. In 
continuous mode, due to the fast reaction, DMF, DMSO 
and DMAc show the highest STY of around 10 – 20 
mg mL-1reactor min-1.  
Figure 9: Calculated STY for the batch and continuous 
process in logarithmic scaling 
In conclusion, the superior performance of the 
continuous process can mainly be attributed to the 
possibility to operate at high temperatures. Although 
similar temperatures could also be reached in a sealed or 
pressurized batch reactor, the distinct advantage of a 
high surface to volume ratio and therefore excellent heat 
transfer properties of the continuous reactor would still 
lead to an advantage over a pressurized batch reactor. 
The batch reactor would need longer heating and cooling 
times and therefore an overall longer processing time 
rendering the fast reaction times useless. In addition, 
higher safety properties usually attributed to continuous 
systems and low cost for the commonly available 
materials are distinct advantages of the continuous 
process. 
CONCLUSIONS 
In this contribution, a continuous process for the 
intensification of the Krapcho dealkoxycarbonylation 
reaction is established and the synthesis of the pharma-
ceutically relevant molecule DHBD is studied as model 
process in detail. To assess the performance of the 
continuous reactor it is compared to the original batch 
process.  
It was found that the dealkoxycarbonylation can be 
significantly intensified in the continuous reactor due to 
the high reaction temperatures possible, resulting in a 
reaction time reduction from 3 h in batch to < 3 min in 
the continuous reactor. Exploiting the pressurized 
reaction conditions in the continuous reactor, the choice 
of solvent can be broadened significantly. It was found, 
that all aprotic-polar solvents under investigation are 
principally suited as reaction medium since similar rates 
were measured. However, due to the higher solubility 
DMSO, DMF and DMAc are preferred. 
Compared to the batch process, STY in the continuous 
reactor is one to two orders of magnitude higher when 
operated under higher temperatures that cannot be 
realized in the batch reactor due to boiling of the reactant 
mixture. 
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NOMENCLATURE 
cR [mmol mL-1] reactant concentration 
di [mm] inner diameter
EA [J mol-1]  activation energy  
k [s-1] reaction rate constant  
k0 [s-1] frequency factor  
L [m] length of the coil-reactor 
M [g mol-1] molar mass 
R [J K-1 mol-1] universal gas constant 
ρS [g mL-1]  solvent density  
S [mg mL-1] solubility 
STY [mg mL-1 min-1] space time yield 
T [°C], [K] temperature 
VR [mL] reactor volume  
V̇ [mL min-1] volumetric flow rate 
XR [-] reactant conversion 
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ABSTRACT 
The dissolution of spray-dried amorphous solid dispersions consisting of paracetamol and PVP VA 64 at room 
temperature leads to the formation of different systems, depending on the drug/polymer ratio. Aqueous systems at room 
temperature with poor paracetamol/PVP VA 64 ratio are transparent solutions, while higher drug loads lead to phase 
separation of the solution. PVP VA 64 is known as thermoresponsive polymer. The aim of the study was to investigate 
the dissolution behaviour of these amorphous solid dispersions in water and their influence on the thermoresponsive 
behaviour of this polymer. Therefore, the demixing temperature was determined using DSC, since a change in the system 
constitutes an endothermic process. It could be shown that PVP VA 64 has lower critical solution temperature (LCST) 
behaviour around 70 °C, which decreases with increasing content of paracetamol due to the complex formation between 
the polymer and paracetamol. 
Keywords: amorphous solid dispersion, thermoresponsive polymer, dissolution, lower critical solution temperature 
INTRODUCTION 
A large number of new active pharmaceutical 
ingredients shows poor water solubility. Amorphous 
solid dispersions (ASD) are a common approach to 
improve solubility and bioavailability. [Grohganz 2014] 
The dissolution of ASD in water or physiological media 
can lead to super-saturation and two-phase separation, 
known as liquid liquid phase separation (LLPS) [Saboo, 
2019]. 
Many polymers, which might be used for ASD, are 
known to separate into two phases when heating or 
cooling their aqueous solution. Two different beha-
viours of the so-called thermoresponsive polymers have 
to be distinguished: If the phase separation occurs 
during heating, the upper critical solution temperature 
(UCST) can be determined. If this happens during 
cooling, the lower critical solution temperature (LCST) 
can be measured. At this temperature, the system 
changes between one and two phases. A polymer-rich 
and polymer-poor phase are formed in the separated 
system. [Aseyev, 2011] Additives can increase or 
decrease the LCST [Van Durme, 2005]. 
The aim of the study was to investigate the dissolution 
behaviour of ASD, consisting of paracetamol and PVP 
VA 64, in water and their influence on the 
thermoresponsive behaviour of this polymer. 
EXPERIMENTAL METHODS 
Materials 
Paracetamol was a generous gift from STADA, 
Germany. PVP VA 64 was kindly donated by BASF, 
Germany. Demineralized water was used for solutions. 
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Amorphous solid dispersions (ASD) 
Preparation of ASD was done by spray drying using a 
Büchi Mini-Spray Dryer B-191. Paracetamol and PVP 
VA 64 were dissolved in demineralized water in ratios 
of 1 : 9 (total concentration of mixture in aqueous 
solution 12.0 % (m/v)), 2 : 8 (6.0 %) and 3 : 7 (4.0 %). 
The following conditions were used for spray drying: 
inlet temperature 80 °C, outlet temperature 45 °C to 
50 °C, pump rate 7 %, aspirator flow rate 100 %. 
Physical mixture (PM) 
The PM of drug and polymer (same ratios as for ASD) 
were mixed in a TURBULA® mixer for ten minutes.  
Differential Scanning Calorimetry (DSC) 
The solutions were analysed in aluminum pans on a 
Mettler Toledo DSC 1 with HSS7 sensor. The mea-
surement was performed in duplicate at a heating rate of 
5 K/min between -10 °C to 85 °C, depending on the 
estimated demixing temperature. The onset temperature 
of the endothermic process was determined [Van 
Durme, 2004]. All measurements were analysed under 
nitrogen purge. 
RESULTS 
Dissolution of ASD in water 
Various systems made of paracetamol, PVP VA 64 and 
water (see Figure 1) were manufactured and optically 
evaluated at room temperature. 























Figure 1: Ternary phase diagram of paracetamol, 
PVP VA 64 and water at room temperature. 
Samples of the pure polymer and mixtures of 
paracetamol and the polymer in the ratio 1 : 9 (green 
line) show transparent solutions in water at room 
temperature, while mixtures in the ratio 2 : 8 (yellow 
line) are opalescent up to a concentration of 25 % PVP 
VA 64. Mixtures in the ratio 3 : 7 (red line) are in the 
form of an emulsion during stirring, while two-phase 
separation can be observed without moving the system.  
LCST of ASD and PM 












PVP VA 64 ratio [%]
LCST ~ 22.9 °C 
n = 2
Figure 2: Demixing temperature (Tdem) of ASD 2 : 8 as 
a function of PVP VA 64 content; mean ± SD. 
The demixing temperatures were determined for dif-
ferent concentrations of PVP VA 64. Below this tem-
peratures the system is a transparent solution. In the near 
of the curve, the system becomes opalescent (see picture 
1, Figure 2). Turbidity can be detected above the curve 
(see picture 2, Figure 2). Below the LCST there is a clear 
solution for each polymer concentration. The phase 
transition is reversible.  
Table 1: LCST of ASD and PM for different systems. 
Sample  





pure PVP VA 64 - 69.7 
1 : 9 52.6 53.4 
2 : 8 22.4 22.9 
3 : 7 14.2 14.7 
The LCST decreases with increasing amount of 
paracetamol (absolute data not shown). The results for 
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DISCUSSION 
A large number of polymers exhibits thermoresponsive 
behaviour in aqueous solution [Aseyev, 2011]. Below 
the LCST the polymer chains are hydrated and thus 
water-soluble, resulting in a transparent solution. 
Temperatures above LCST lead to aggregation of the 
polymer chains by hydrophobic interactions, which 
results in turbidity of the solution and later in phase 
separation. [Van Durme, 2005] 
By forming a complex of paracetamol and PVP VA 64, 
the LCST decreases with increasing part of paracetamol. 
The formation of hydrogen bonds [Afrasiabi Garekani, 
2003] or Van-der Waals forces [Wen, 2005] between the 
molecules are discussed as reasons. 
The aqueous solutions of pure PVP VA 64 as well as 
ASD and PM in the ratio 1 : 9 are transparent at room 
temperature because their LCST is between 50 °C and 
70 °C. Close to the critical point, solutions become 
opalescent [Monval, 1939]. The LCST of aqueous 
solutions of ASD and PM in the ratio 2 : 8 is around 
room temperature, resulting in opalescence. 
Aqueous systems with drug/polymer ratio of 3 : 7 have 
a LCST that is lower than room temperature. Such 
mixtures result in an emulsion that separates rapidly into 
two phases when it is no longer shaken. The so-called 
liquid liquid phase separation is well known for ASD 
[Saboo, 2019]. Previous experiments have shown that 
on the one hand an aqueous, drug-poor phase with a drug 
concentration similar to the amorphous solubility 
results. On the other hand, a drug-rich phase is formed 
and it is discussed that it serves as a drug reservoir 
[Saboo, 2019]. 
CONCLUSIONS 
It could be shown that PVP VA 64 is a thermoresponsive 
polymer with LCST behaviour. With increasing part of 
paracetamol the LCST decreases due to complex 
formation between the polymer and drug. The results for 
the different ratios are similar for ASD and PM. 
As already mentioned, phase separated systems may act 
as drug reservoirs and therefore be of interest for 
modified drug release. The aim of the next investigation 
is to study the drug permeation from phase separated 
systems through Caco-2 cells.  
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LIGANDS FOR M-NHC SYNTHESIS: CONTINUOUS FLOW DI-N-ALKYLATION  
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ABSTRACT 
The successful transfer from batch to a continuous flow process in a fixed bed reactor of a ligand in metalorganic API 
synthesis, the diazolium salt 1,3-methyl-benzoimidazol-3-ium iodide, is presented. Results show similar yields and 
conversion rates at corresponding process parameters in batch and continuous mode. By exceeding temperature limitation 
of a non-pressurized batch process, the pressurized continuous reactor system shows the potential for outperforming the 
batch synthesis regarding space time yield. Hence, process intensification by continuous flow presents itself as a viable 
approach for the heterogeneous di-N-alkylation of diazoles. Alternative basic reagents and solvents further enhance the 
viability of a continuous approach by addressing limitations such as side reactions and solubility of the reagent. 
Keywords: Continuous flow synthesis, fixed bed reactor, heterogeneous synthesis, 1H-benzimidazole
INTRODUCTION 
Over the last decades imidazole and benzimidazole 
derivatives gained interest due to their capability of 
forming stable N-heterocyclic carbenes (NHC) 
[Dröge 2010]. Since then NHC have been widely used 
as ligands in organometallic complex synthesis (M-
NHC) [Jacobsen 2009]. The initial derivatives of e.g. 
benzimidazole can be prepared in various forms 
adjusting their properties and possible applications. 
Hence diazoles can be considered as scaffold chemicals 
for e.g. M-NHC synthesis with applications in catalysis 
and especially as active pharmaceutical ingredients 
(API) [Rubbiani 2011; Oehninger 2013; Aher 2014]. 
Carbenes are often synthesized by deprotonation of a 
corresponding diazolium salt. Diazolium salts can be 
synthesized e.g. by reductive cyclization which requires 
and metal catalysts (e.g. Pd) or by N-alkylation of 
diazoles [Boiani 2005; Jacobsen 2009; Guillena 2010; 
Grieco 2015]. Both routes are often also time-
consuming. A transfer to continuous processing offers 
advantages due to process intensification and low 
holdup e.g. reducing overall time required for total 
conversion and precise as well as fast process 
controllability.  
By establishing the N-alkylation in presence of a solid 
basic reagent and a halogenated alkylating agent for 
continuous operation another downside of both batch 
and continuous approaches can be addressed. Syntheses 
of diazolium salts can be performed with an abundant 
and non-expensive basic reagent such as K2CO3 instead 
of costly catalysts [Sauk 2019]. Catalysts which are 
often discarded or offer limited regeneration cycles.  
In this work the successful transfer of the synthesis of 
1,3-dimethyl-1H-benzoimidazol-3-ium iodide (DBI) 
from batch to continuous processing is presented. 
Synthesis is performed in a continuous flow fixed bed 
reactor via a di-N-alkylation of 1H-benzimidazole (see 























Figure 1: Assumed reaction scheme of the 2-step synthesis of 
1,3-methyl-benzoimidazol-3-ium iodide (DBI) in the presence 
of a solid base (K2CO3) and methylene iodide (MI). Inter-
mediate: 1-methyl-1H-benzoimidazol-3-ium iodide (MBI) 
In addition, the viability but also limitations of this 
process are addressed such as negative effects of 
elevated reactor temperature on conversion rates and 
occurrence of side reactions. Chances to overcome these 
limitations and further enhance the process by screening 
for alternative solvents and basic reagents are addressed 
as well. 
CONTINUOUS FLOW SYSTEM 
Figure 2 presents the experimental set-up. The conti-
nuous flow synthesis is performed in an electrically 
heated HPLC column (L = 250 mm, ID = 8 mm). 
Peripheral components are two HPLC pumps as well as 
a mixer combining the reagents before entering the 
column. Subsequent to the column the back-pressure 
regulator (7 bar) protected by a filter secures constant 
system pressure. Valves (magnetic and manual) enable 
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sampling at certain stages of the process as well as 
switching between conditioning, cleaning and synthesis. 
In addition, a conductivity sensor is integrated enabling 

































Figure 2: Process flow chart of the continuous flow synthesis 
of diazolium salts in a fixed bed reactor 
CONTINUOUS FLOW PROCESSING 
Figure 3: Comparison of conversion to DBI in batch and 
continuous processing with K2CO3 as basic reagent 
(r = 5 molMI molBI-1) 
By performing the continuous synthesis at similar 
process parameters as the batch synthesis both show a 
good agreement (see Figure 3). In addition, the synthesis 
progress can be approximated by a kinetic model for 
consecutive reactions of first order as expected from the 
reaction scheme (see Figure 1). The pressurized 
continuous system enables higher reaction temperature 
(T > 82°C for acetonitrile) hence outperforming the 
batch system regarding accessibility (e.g. sampling), 
safety and potentially space time yield STY. Figure 4 
shows the beneficial influence of the elevated fixed bed 
temperature on the synthesis. Nonetheless higher 
temperatures result in yet unknown side reactions 
reducing overall yield and purity of the product. 
Figure 4: Influence of temperature on the reactor outlet com-
position in a continuous flow fixed bed reactor (K2CO3; n = 1 
per temperature; V̇ = 200 µL min-1; r = 2.5 molAX molBI-1) 
Thus, alternate synthesis approaches by changing the 
basic reagent and also solvent are addressed as well.  
SCREENING OF BASE AND SOLVENT 
Besides unfavorable side reactions, the formation of 
KHCO3 (see Figure 1) and possible decomposition to 
CO2, H2O and K2CO3 thus degradation of the fixed bed 
is ubiquitous. Hence screening for alternative abundant 
and non-expensive basic reagents is performed. 
Figure 5: Conversion to DBI with none and a selection of basic 
reagents from the groups of metal oxides, activated carbon, 
zeolites and alkali (r = 2.5 molMI molBI-1, batch, n = 3) 
Figure 5 shows the conversion to the product when 
different basic reagents are applied in a batch synthesis. 
CaO offers the best similarity to K2CO3, whereas basic 
zeolites (NaMSXK) or basic activated carbon (RST) 
exhibit good conversion but also adsorption of the 
product, intermediate as well as initial reagent. 
Adsorption has been observed for several types of 
activated carbon as well as zeolites, hence both 
substances are not applicable for synthesis or as 
subsequent adsorbents for purification of the synthesis 
solution. Also, the necessity of a basic reagent is shown 
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indicates the lowest and stagnating conversion to the 
product. 
Figure 6: Conversion to DBI for different synthesis solvents 
(K2CO3, T = 50 °C, r = 5 molMI molBI-1, batch, n = 3) 
Batch syntheses for a selection of aprotic polar solvents 
have been conducted as shown in Figure 6. Regarding 
the low boiling point of acetone, batch syntheses have 
been performed at 50 °C. Both THF and acetone show 
low conversion rates as well as a decreasing ratio of 
product. This decrease is related to a low solubility of 
the product and precipitation rendering both solvents 
unsuitable for continuous operation. DMF exhibits 
conversion rates exceeding acetonitrile by a factor of 4 
similar to a reaction in acetonitrile at 70 °C. 
Results of both base and solvent screening indicate a 
high potential of e.g. calcium oxide (CaO) and DMF. 
Hence increase of space-time-yield (STY) by a factor of 
approximately up to 49 is possible due to high solubility 
and conversion rates of the reagents as well as low 
occurrence of side reactions. 
CONCLUSIONS AND OUTLOOK 
Continuous flow synthesis in a fixed bed of an 
exemplary diazolium salt has been successfully 
performed. In addition, first results of a selection of 
alternative basic reagents and solvents have been 
presented. Results show the potential and viability of a 
fixed bed reactor with basic reagents for di-N-alkylation 
of diazoles though further investigations on column 
degradation as well as side reaction must be conducted. 
Current investigation focuses on long term stability of 
the fixed bed as well as identification and reduction of 
side reactions.  
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ABSTRACT 
Parenteral nanoemulsions are regarded as biocompatible drug delivery systems for lypophilic drugs. When it comes to 
delivering actives to the brain as a target site, prolonged circulation time is desirable. The objective of this study was to 
conduct physicochemical characterization of PEGylated nanoemulsions as prospective carriers for enhanced brain 
delivery, using diazepam as a model active substance for brain targeting. Nanoemulsions were prepared by high 
pressure homogenization method and characterized regarding droplet size, zeta potential, pH, conductivity, viscosity 
and in vitro release profile. PEG2000-DSPE and PEG5000-DPPE were used for PEGylation. All the formulations were 
autoclaved and stored at room temperature. After 2 months there were no significant changes in physicochemical 
parameters in autoclaved formulations which rendered them as good potential templates to incorporate drugs for brain 
targeted delivery. 
Keywords: PEGylated nanoemulsions, diazepam, physicochemical characterization, in vitro release 
INTRODUCTION 
Nanoemulsions are regarded as biocompatible drug 
delivery systems which are especially beneficial for 
parenteral application of water insoluble actives. It is 
considered that the oil droplets are rapidly removed 
from the circulation by the components of the 
mononuclear phagocytic system (MPS) [Hormann, 
2016]. When it comes to brain as a target site, 
prolonged circulation time of oil droplets is beneficial 
as it allows more time for an active to reach and cross 
the blood brain barrier. One of the strategies used to 
prolong the circulation time of parenteral 
nanoemulsions is coating the surface of oil droplets 
with polyethyenglicol (PEG) chains. PEG chains 
provide protection against detections by opsonins from 
plasma and MPS removal from the circulation by 
increasing the surface hydrophilicity [Kandadi, 2011]. 
Diazepam is available on the market as nanoemulsion 
preparation (Diazelmus, Kabi-Pharmacia, Sweden) 
and is commonly used benzodiazepam [Đorđević, 
2013]. The aim of this study was to develop and 
characterize PEGylated parenteral nanoemulsions as 
possible carriers for prospective delivery of actives to 
the brain, using diazepam as a model active substance. 
RESEARCH CONCEPT 
Nanoemulsions (non-PEGylated - NPEG and 
PEGylated) were prepared by high pressure 
homogenization method, autoclaved and characterized 
regarding droplet size, zeta potential, pH and 
conductivity both initially and after 2 months of 
storage at room temperature. Additionally, viscosity 
measurements and in vitro release study of the 
formulations were performed. 
1. Nanoemulsion preparation and sterilization
Diazepam loaded nanoemulsions (2mg/g) were 
prepared using high pressure homogenization method 
https://doi.org/10.24355/dbbs.084-202001220921-0
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at room temperature. Water and oil phase were 
prepared separately. Aqueous phase (glycerol, 
polysorbate 80, highly purified water and 0,1 M 
NaOH) was added to oil phase (soybean oil, medium 
chain triglycerides, soybean lecithin, 
butylhydroxytoluene and diazepam) and homogenized 
using rotor stator homogenizer (IKA Ultra-Turrax® T25 
digital) at 8000 rpm for 3 minutes. Formulations were 
further homogenized by high-pressure homogenizer 
(EmulsiFlex-C3, Avestin Inc., Canada) for 9 cycles at 
500 bar. PEGylation agents used were PEGylated 
phospholipids: PEG2000-DSPE (P2) or PEG5000-
DPPE (P5), which were added to the aqueous phase at 
concentration of 0,1% or 0,3% (P2_0.1%, P2_0.3% 
P5_0.1%, and P5_0.3%). All formulations were 
sterilized in autoclave at 121°C for 15 minutes. 
2. Size and zeta potential measurements
Formulations were characterized regarding the mean 
droplet size (intensity weighed mean diameter, Z-Ave), 
droplet size distribution - polydispersity index (PDI) 
and zeta potential (ZP) by Zetasizer Nano ZS90 
(Malvern Instruments Ltd., Worcestershire). In order to 
confirm the size measurements and check for larger 
droplets presence laser diffraction measurements were 
performed using Beckman Coulter LS 13 320 
(Beckman Coulter, Inc., Brea, California). 
3. Conductivity, pH and viscosity
Conductivity and pH measurements were performed to 
test the formulations’ stability after sterilization and 
during storage as well as suitability for parenteral 
application. Viscosity measurements were conducted in 
order to assess the formulations’ syringeability and 
suitability for parenteral application. 
4. In vitro release studies
The drug release was studied by dialysis bag method 
using cellulose membrane with molecular weight cut 
off of 12000. Dialysis bags with 2 ml of the 
formulations were placed in 200 ml of the dissolution 
medium - phosphate buffer pH 7,4 (USP) : methanol = 
80:20 (v/v %). Samples were drown after 0.083, 0.167, 
0.333, 0.67, 1, 2, 4, 8, 12 and 24 hours and analyzed 
for diazepam content by spectrophotometer at 230 nm. 
The release profiles were analyzed with different 
kinetic models: zero order, first order, Higuchi, Baker-
Lonsdale, Korsmeyer-Peppas and Hixon-Crowel 
models (DDSolver packet for Microsoft Excel 
apication). 
RESULTS 
The size measurements preformed initially and after 2 
months of storage showed that Z-ave was in the range 
of 180 nm to 220 nm, with PDI below 0,2 for both non-
autoclaved and autoclaved samples (Figure 1.). Laser 
diffraction measurements showed that d100 was below 1 
µm for all samples.  
 
 
Figure 1. Z-ave and PDI results of the non-autoclaved 
formulations 
Zeta potential for all the samples was between -30 and 
-50 mV (Figure 2). Non-autoclaved samples had
significant changes in pH (decreasing from around 7 to
about 5 within 2 months) and conductivity (increasing
from around 100 µS/cm to around 400 µS/cm). As for
the autoclaved samples, pH and conductivity remained
stable at around 7 and 100 µS/cm, respectively.
Viscosity was around 5 mPa*s for all samples.
 
 
Figure 2. Zeta potential for the non-autoclaved 
formulations. 
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Figure 3. In vitro release study – cumulative drug 
release 
DISCUSSION 
All the PEGylated formulations had higher droplet size 
comparing to the non-PEGylated formulation and Z-
ave increased with increasing concentration of 
PEGylated phospholipids. Droplet size was higher 
when using PEG5000-DPPE compared to PEG2000-
DSPE, which can be explained with the longer of PEG 
chains in PEG5000-DPPE formulations. Nevertheless, 
the Z-ave was below 500 nm for all the formulations, 
with no droplets larger than 1 µm detected, which is 
concordant with USP requirements. PDI remained 
below 0.2 showing narrow size distribution. Given that 
the formulations are stabilized with soybean lecithin, 
zeta potential values at around -40 mV were expected. 
During storage and autoclaving phospholipids and oils 
can succumb to hydrolysis, which in turn leads to 
increased negative zeta potential value. This could be 
perceived as beneficial given that the higher zeta 
potential values indicate better stability, but in this case 
it is a consequence of free fatty acid liberation, which 
leads to pH value decrease, which in turn promotes 
further degradation and destabilization in 
nanoemulsions [Klang, 2011]. Interestingly, in 
obtained autoclaved nanoemulsions showed better 
stability in terms of maintaining pH and conductivity 
values compared to the unsterilized formulations, 
which requires further insight . Lower absolute zeta 
potential values can been detected in formulations 
containing PEG5000-DPPE versus the non-PEGylated 
and the formulations containing PEG2000-DSPE, 
probably due to longer PEG chains increasing 
hydrophilicity on the surface. [Kandadi, 2011]. 
Interestingly, it appeared that the autoclaved samples 
showed better stability compared to the non-autoclaved 
samples regarding pH and conductivity measurements. 
Low viscosity of the formulations rendered them safe 
for parenteral use and showed that adding PEGylated 
phospholipids did not significantly increase the 
formulations’ viscosity. 
In the in vitro release study it could be observed that 
the highest release of diazepam was from the non-
PEGylated formulation (Figure 3). That release profile 
was similar with the formulation containing 0,1 % 
PEG2000-DSPE, suggesting that the used 
concentration was too low to coat the nanoemulsion 
droplet surface and slow down the release. The slowest 
release was observed when using 0,3 % PEG2000-
DSPE compared to both the non-PEGylated 
formulation and the formulations containing PEG5000-
DPPE, which could be explained by PEG2000-DSPE 
forming more rigid packing at the interface comparing 
to DPPE chains, therefore causing slower release of the 
incorporated diazepam. This was corroborated by the 
fact that the Higuchi model, which describes drug 
release as a diffusion based process founded in the 
Fick’s law was the best fit to describe the profiles 
(highest R2, Radj2 and the lowest AIC - Akaike
Information Criterion) [Costa, 2001]. Higuchi 
dissolution constants were lower for the formulations 
containing PEGylated phospholipids which indicated 
that they slow down the diffusion of the diazepam from 
the droplets. 
CONCLUSIONS 
Initial physicochemical characterization suggested that 
investigated nanoemulsions were appropriate for 
parenteral application. Release profiles showed that the 
PEGylated formulations could delay the release of the 
incorporated drugs, which could be beneficial when 
prolonged release of the active is required. They could 
be considered as prospective template carriers for the 
water insoluble actives when prolonged circulation 
time is desired, for example for brain targeted delivery. 
However, further investigations are necessary in order 
to prove pharmacokinetic advantages in vivo, like 
pharmacokinetic study in animal models. 
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ABSTRACT 
Filamentous microorganisms represent the majority of natural producers of antibiotics and other active pharmaceutical 
ingredients (APIs). Lentzea aerocolonigenes is a filamentous actinomycete producing the antitumor antibiotic 
rebeccamycin. The addition of glass beads (100 g/L, Ø = 969 μm) in shake flask cultivations led to a significant increase 
in rebeccamycin production compared to an unsupplemented cultivation by inducing mechanical stress. To achieve larger 
amounts of rebeccamycin a scale-up was conducted. A bubble free membrane aeration was chosen to reduce the power 
input to stirrer and particle induced stress. Glass bead addition (50 g/L, Ø = 969 μm) in this membrane aerated stirred 
bioreactor increased rebeccamycin concentration compared to an unsupplemented cultivation as well. Moreover it 
reduced biomass growth on the aeration membrane which is a widespread challenge in membrane aerated bioreactors. 
Keywords: membrane aeration, filamentous microorganisms, particle enhanced cultivation, mechanical stress 
INTRODUCTION 
Lentzea aerocolonigenes, belonging to the filamentous 
microorganisms, produces the antitumor antibiotic 
rebeccamycin. The microorganism exhibits a complex 
morphology ranging from freely dispersed mycelia to 
dense pellets [Pommerehne et al., 2019]. The 
morphology is linked to the product formation and can 
be controlled by e.g., inoculum concentration and 
viability, pH, medium composition, hydromechanical 
stress, addition of inorganic salts or particles [Walisko 
et al., 2015]. Rebeccamycin formation in 
L. aerocolonigenes was increased by the adjustment of
mechanical stress induced by glass particles in shake
flask scale [Walisko et al., 2017]. Scale up from shake
flasks to laboratory scale bioreactors is often linked to
increased mechanical stress and since is an important
factor to be considered. Membrane aerated bioreactors
show a reduced power input since no bubbles are
present.
RESEARCH CONCEPT 
Cultivations of L. aerocolonigenes in shake flask scale 
were conducted in 250 mL flasks with 4 baffles and 
50 mL filling volume. A preculture was inoculated with 
1 mL of frozen mycelium and incubated for 2 days at 28 
°C and 120 min-1. 300 µL of this preculture were used 
for inoculation of the main culture. Glass particles were 
added for adjustment of the induced mechanical stress at 
the beginning of the cultivation. Different size ranges 
and concentrations of glass beads were investigated. The 
flasks were incubated on an orbital shaker at 120 min-1 
(50 mm amplitude) at 28 °C for 10 days. The growth 
medium consisted of 4 g/L glucose, 4 g/L yeast extract 
and 10 g/L mat extract with a pH of 7.2. 
A scale up to a stirred bioreactor (Applikon 
Biotechnology, The Netherlands) with 1.2 L filling 
volume was performed. Aeration in this bioreactor was 
conducted via an oxygen permeable silicone tube (wall 
thickness = 0.2 mm; diameter = 2.9 mm, Reichelt 
Chemietechnik, Germany). The tube was wound around 
the installations inside the bioreactor and the end was 
placed above the liquid to provide additional headspace 
aeration. The length of the tubing as well as the aeration 
rate and the stirrer speed were varied. When glass 
particles were added a mean size of Ø = 969 μm was 
chosen. Cultivations were inoculated with 7.5 mL of a 
2-day preculture and grown at 28 °C for 10 days with
daily sampling.
https://doi.org/10.24355/dbbs.084-202001220921-0
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Cell dry weight (CDW) was determined gravimetrically. 
Substrate and product quantification were conducted as 
described by [Walisko et al., 2017]. 
RESULTS AND DISCUSSION 
L. aerocolonigenes was first investigated in shake flask
scale, where the addition of glass beads showed
increased product formation. Different glass bead sizes
and concentrations were tested and the optimal
rebeccamycin concentration of about 70 mg/L was
achieved with a mean glass bead diameter of 969 μm in
a concentration of 100 g/L. An unsupplemented control,
however, only provided 5 mg/L rebeccamycin (Fig. 1).
Figure 1: Cell dry weight concentration and 
rebeccamycin concentration of shake flasks cultivations 
without and with 100 g L-1 glass beads after 10 days of 
cultivation. 
This process should be transferred to bioreactor scale to 
provide larger amounts of rebeccamycin since larger 
volumes are used. A certain amount of mechanical stress 
was beneficial for rebeccamycin production, however, 
excessive stress decreases product formation [Walisko 
et al., 2017]. Since conventional aeration in bioreactors 
creates additional stress, a bubble free membrane 
aeration was chosen. 
A first cultivation without glass beads led to a maximum 
of 12 mg/L rebeccamycin (Fig. 2) which is comparable 
to an unsupplemented shake flask cultivation. During 
this cultivation, however, excessive biomass growth on 
the silicone membrane was observed (Fig 3, left). The 
addition of glass beads reduced the growth of biomass 
on the silicone tube (Fig. 3, right). The moving glass 
beads lead to a permanent abrasion ensuring an 
improved oxygen transfer. 
Figure 2: Rebeccamycin concentration of a silicone 
membrane aerated bioreactor cultivation without glass 
particles at an agitation rate of 400 min-1 and an aeration 
rate of 0.2 L/min (0.4 L/min during exponential phase).  
Figure 3: Biomass growth on silicone membrane 
without (left, 5 m tube length) and with glass beads 
(right, 50 g/L, Ø = 969 μm, 2.5 m tube length) added to 
the cultivation. 
Moreover, the cultivation with glass beads resulted in an 
increased rebeccamycin concentration (Fig. 4). With 
50 g/L glass beads of 969 μm mean diameter a 
maximum rebeccamycin concentration of 42 mg/L was 
provided. 
Figure 4: Rebeccamycin concentration of a silicone 
membrane aerated bioreactor cultivation with glass 
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particles (50 g/L, Ø = 969 μm) at an agitation rate of 650 
min-1 and an aeration rate of 0.2 L/min (0.4 L/min during 
exponential phase). 
CONCLUSIONS 
Successful cultivations of L. aerocolonigenes in a 
membrane aerated stirred bioreactor were conducted. 
The use of membrane aeration through a silicone tube 
reduces the mechanical stress induced on the 
microorganism and additionally avoids foaming which 
is often problematic especially for complex media. The 
in this paper presented combination of membrane 
aeration and glass bead addition provides further 
advantages. The increase of product formation by the 
addition of glass beads as seen in shake flasks could also 
be observed in bioreactor scale. Furthermore the glass 
beads decrease the biomass growth on the silicone 
membrane since they are causing a permanent abrasion. 
This makes membrane aerated bioreactors a promising 
cultivation platform, especially for other filamentous 
microorganisms. 
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ABSTRACT 
Artemisinin-based combination therapies are recommended by the World Health Organization to treat malaria, one of 
the most abundant infectious diseases in the world. Recently, a novel production route, which combines the extraction 
and the catalyzed chemical synthesis, has been shown to be a promising sustainable processing alternative [Triemer, 
2018]. To exploit its mechanism, operational settings and limits, mathematical modeling might be beneficial when 
thorough system insight is required. In a first step, we consider the catalyzed synthesis step from dihydroartemisinic 
acid to artemisinin, and we show that only a subset of the parameters of the considered model is identifiable with the 
available sparse data using a singular value decomposition approach. In a second step, within the framework of design 
of experiments (DoE), we demonstrate the effect of additional experimental data to overcome the non-identifiability 
problem of the model parameters. 
Keywords: parameter identifiability, design of experiments, parameter sensitivities, singular value decomposition, 
antimalarial artemisinin synthesis
INTRODUCTION 
In the case of antimalarial drugs, artemisinin is an 
essential precursor to several active pharmaceutical 
ingredients (APIs). Aiming for lower costs, the two-step 
partial synthesis of dihydroartemisinic acid (DHAA) to 
artemisinin has gained interest in academia and 
industry. To improve the production of artemisinin, 
process systems engineering concepts can be applied. 
For instance, mathematical process models may predict 
the best catalysts, solvents, reaction conditions, as well 
as the overall reactor type and operating conditions. 
However, when applying model-based process design 
concepts, the risk of false predictions and 
misinterpretations depends critically on data quality 
and uncertainties of the identified model parameters, 
respectively. Besides a valid process model and 
informative experimental data, the model parameters 
have to be theoretically identifiable. In the literature, 
various identifiability concepts exist, but only some of 
these methods apply to complex, non-linear process 
models. In this study, we determine the local 
parameter sensitivity matrix for a simplified process 
model of the two-step partial synthesis of DHAA to 
artemisinin, and we analyze the parameter 
identifiability of this process model using a singular 
value decomposition approach [Stigter, 2017]. To 
improve the parameter identifiability, we also apply a 
model-based design of experiments (DoE) concept that 
demonstrates the effect of additional experimental 
data on the parameter identifiability. 
METHODS 
Frequently, dynamic processes are described via 
ordinary or partial differential equation systems, and 
the model parameters 𝑝𝑝 are identified via numerical 
optimization methods minimizing the differences 
between simulation results and experimental data. The 
parameter identification problem, however, might be 
ill-posed in the case of non-identifiable model 
parameters. In DoE and the identifiability analysis, the 
local parameter sensitivity matrix is an essential 
measure [Schenkendorf, 2018] and is defined as: 
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where 𝒚𝒚𝒊𝒊 is the ith model response function and 𝒑𝒑𝒋𝒋 the 
jth model parameter. If the sensitivity matrix 𝑺𝑺𝑺𝑺 is 
singular, that is, the matrix is rank deficient, the model 
parameters cannot be identified properly [Stigter, 
2017]. To test the rank of the 𝑺𝑺𝑺𝑺, the singular value 
decomposition can be used: 
𝑺𝑺𝑺𝑺(𝒕𝒕𝟎𝟎, … , 𝒕𝒕𝒌𝒌,𝒑𝒑) = 𝒖𝒖𝟏𝟏𝝈𝝈𝟏𝟏𝒗𝒗𝟏𝟏𝑻𝑻 + ⋯+ 𝒖𝒖𝒒𝒒𝝈𝝈𝒒𝒒𝒗𝒗𝒒𝒒𝑻𝑻, 
where 𝛔𝛔𝒊𝒊 are the singular values, 𝒖𝒖𝒊𝒊 are the left-singular 
vectors, and 𝒗𝒗𝒊𝒊 are the right-singular vectors. Here, zero 
singular values indicate a lack of identifiability, and the 
non-zero elements of the corresponding singular 
vectors 𝒗𝒗𝒊𝒊 reveal the non-identifiable parameter or 
parameter combinations. 
RESULTS 
The details of the implemented two-phase process 
model of the partial synthesis of artemisinin, which has 
10 system states and 7 unknown model parameters, 
can be found in [Triemer, 2016]. Moreover, we 
assumed that 7 of the 10 system states are measurable. 
In Fig. 1, the resulting singular values are shown. The 
singular values σ𝑖𝑖 , 𝑖𝑖 ∈ {5,6,7} are close to zero, that is, 
the model parameters are non-identifiable. The related 
singular vectors 𝒗𝒗𝑖𝑖 , 𝑖𝑖 ∈ {5,6,7} clearly show that only a 
minor subset {𝒑𝒑3,𝒑𝒑6} of the model parameters can be 
identified in principle; see Fig. 2. In turn, the model 
parameters {𝒑𝒑4,𝒑𝒑5} and the combination of 𝒑𝒑1,𝒑𝒑2, and 
𝒑𝒑7 are non-identifiable. 
Figure 1: Singular values of the local sensitivity matrix. 
Figure 2: Elements of the right-singular vectors of the 
singular values 𝜎𝜎𝑖𝑖 , 𝑖𝑖 ∈ {5,6,7}. 
When applying DoE and increasing the number of 
experimental data, we observed no improvement 
regarding the identifiability. Thus, there is a structural 
lack of parameter identifiability of the studied process 
model of the partial synthesis of artemisinin. 
CONCLUSIONS 
We studied the identifiability of a given process model 
of the partial synthesis of artemisinin. Based on the 
sensitivity matrix and its singular values, we proved that 
the model parameters are non-identifiable and that 
additional experimental data do not result in a proper 
parameter identification problem. Future work will 
combine DoE and model reduction techniques to 
improve the parameter identifiability, leading to 
reliable model-based process analysis and design 
results for an optimal artemisinin synthesis. 
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ABSTRACT 
The delivery of poorly water-soluble bioactives, including active pharmaceutical ingredients (API) and nutraceutical 
components is of great interest for existing drugs and new drug developments, cosmetic formulations, functional foods 
and nutraceuticals. This article presents a novel patented technology called PGX Technology, which utilizes pressurized 
gas expanded (PGX) liquids to dry, micronize, purify and functionalize water-soluble polymers. PGX Technology can 
generate open-porous nanostructured polymer carriers composed of one or several water-soluble polymers forming 
powders, granules, nano-fibrils, aerogels and exfoliated nano-composites with specific surface areas (SSA) ranging from 
tens to several hundred m2/g. Such mesoporous water-soluble carrier systems can be impregnated with a bioactive by 
means of adsorptive precipitation, utilizing supercritical carbon dioxide, leading to the uniform deposition of nano-scale 
particles (<120 nm) throughout the porous matrix, forming a bioactive-polymer complex, for example coenzyme Q10 on 
β-glucan (CoQ10-iBG). A nano-dispersion of CoQ10 is formed when such CoQ10-iBG complex is dissolved in water, 
which is stable over 6 months at room temperature. The bioavailability of the CoQ10-iBG complex tested in rats compared 
favorably with a positive control (CoQ10 in triolein) and a commercial CoQ10-cyclodextrin complex. 
Keywords: gas expanded liquid, biopolymer nano-fibers, nano-dispersion, solid dosage form 
INTRODUCTION 
Novel strategies for the formulation and processing of 
poorly water-soluble bioactives and drugs range from 
lipid-based colloidal drug delivery systems (DDS) to 
drug nanosuspensions and innovative solid dosage 
forms such as orodispersible films (ODFs) or 
electrospun fiber mats as drug carriers [Göke, 2018]. 
The generation of drug nanosuspensions can be 
achieved by either bottom-up or top-down methods. 
Top-down methods usually start from larger drug 
particles, which are then reduced in size by applying 
mechanical shear, force or cavitation treatment. Top-
down methods employ milling techniques, such as wet 
milling, colloid milling, jet milling or high-pressure 
homogenization methods, such as micro-fluidization or 
a piston gap technique [Chin, 2014; Wais, 2016]. In a 
bottom-up method the drug is typically dissolved first in 
a suitable solvent and then precipitated by changing 
solubility, which can be achieved in several ways, such 
as the addition of an antisolvent. In such antisolvent 
precipitation processes the method of addition and 
mixing of the antisolvent to the solution becomes critical 
and can be achieved by means of rapid mixing devices, 
ranging from simple stirrers to rotating fixed beds, multi 
inlet vortex mixers and confined liquid impinging jets to 
reach highly turbulent and fast mixing thereby 
controlling supersaturation and nucleation [Chan, 2011]. 
Processing techniques using supercritical fluids (SCF) 
to produce drug nanoparticles/nanocrystals have also 
been developed, which take advantage of the highly 
tunable solvent properties of SCFs [Padrela, 2018]. The 
SCF in such process can be utilized as an antisolvent to 
cause precipitation out of a solution, a solvent for the 
solute or as an additive to facilitate atomization and 
drying [Padrela, 2018; Tabernero, 2012]. Moreover, 
SCF processes were developed for particle formation of 
polymers to be used as carrier delivery systems [Yeo, 
2005]. For polymer processing, the SCF can be 
dissolved in a polymer melt and aid in melting point 
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reduction and atomization, such as in the “Particle 
formation from gas-saturated solution” (PGSS) process, 
leading to highly porous polymer particles and 
agglomerates [Yeo, 2005].  
Pressurized Gas eXpanded (PGX) liquid Technology 
has been developed at the University of Alberta 
[Seifried, 2010], is patented in the US, Europe and 
Canada [Temelli & Seifried, 2016 and 2018] and has 
been scaled-up to demo-scale at Ceapro Inc. [Seifried, 
2019]. This platform technology can purify and dry 
aqueous solutions or slurries of polymers into open-
porous nano-structured particles and fibrils utilizing a 
PGX fluid composed of supercritical carbon dioxide 
(SCCO2) and anhydrous ethanol at mild operating 
conditions of 40°C and 100 bar as drying fluid. With the 
PGX Technology, single and multiple polymers can be 
processed by simply blending polymer solutions or 
suspensions to generate exfoliated nano-composites. As 
well, the water-soluble polymers can be further 
modified by cross-linking during the PGX process, 
allowing generation of tailor-made and tunable delivery 
systems. 
The first objective of this work is to present various 
polymers processed by PGX Technology into open-
porous particles, fibrils and nano-composites with large 
specific surface area (SSA). The next objective is to 
demonstrate that such open-porous PGX biopolymer 
carriers can be loaded with a bioactive forming novel 
bioactive impregnated polymer complexes termed 
“impregnated Polymer compleX” (iPX) by means of 
adsorptive precipitation utilizing SCCO2 [Gurikov, 
2018]. Specifically, PGX processed oat β-glucan was 
loaded with the bioactive Coenzyme Q10 (CoQ10), a 
poorly bioavailable lipophilic substance with 
antioxidant activity. The new complex termed CoQ10-
iBG is compared to a commercial CoQ10-cyclodextrin 
complex in terms of water dispersibility and physical 
nanosuspension stability. Finally, a pilot study 
demonstrating the intestinal bioavailability of CoQ10 
was performed to determine the direct in-vivo intestinal 
bioavailability of CoQ10 from the CoQ10-iBG complex 
compared to a standard food grade and commercial 
crystalline CoQ10 formulations using an intestinal-
lymph cannulated rodent model. 
RESEARCH CONCEPT 
Generation of polymer carrier: PGX Technology 
involves the spraying of an aqueous solution or slurry of 
polymer into a pre-pressurized collection chamber, 
together with a PGX fluid, composed of SCCO2 and a 
water-soluble co-solvent/antisolvent (i.e. ethanol, 
acetone or isopropanol) by means of a coaxial nozzle. At 
the processing conditions, the PGX fluid and aqueous 
phase become completely miscible thereby eliminating 
interfacial tension and capillary forces leading to rapid 
precipitation of the polymer and quick removal of the 
water. Thus, open-porous and unique nanoscale  
morphologies can be generated.  
Loading of bioactive onto polymer carrier: The 
porous polymer carrier generated by PGX is then 
subjected to an adsorptive precipitation process utilizing 
SCCO2 to load a bioactive or drug onto the matrix 
[Gurikov, 2018]. In this process, the bioactive is 
essentially solubilized at elevated pressure and suitable 
temperature in SCCO2 and passed through a bed of 
porous polymer carrier previously prepared using the 
PGX Technology. During this step, the SCCO2 with the 
dissolved bioactive or drug can penetrate the entire 
carrier matrix deep into the porous structure, where it 
can interact with the polymer matrix, leading to 
adsorption of the drug on the polymer. Furthermore, by 
modulating the pressure during the adsorptive 
precipitation process a sudden change of solute 
solubility in the SCCO2 solution can be rapidly induced, 
leading to precipitation of nano-scale deposits of the 
bioactive throughout the matrix [Gurikov, 2018]. For 
this study, an open-porous polymer carrier was 
generated by PGX Technology from oat β-glucan (BG) 
and then loaded with CoQ10 by means of adsorptive 
precipitation as described and characterized elsewhere 
[Liu, 2018; Couto, 2018]. 
Helium Ion Microscopy: For imaging the nanoscale 
features of the various PGX-processed polymers and 
impregnated CoQ10-iBG complex a Helium ion 
microscopy (HiM) analysis was performed on a Zeiss 
Orion NanoFab Helium Ion Microscope (Ostalbkreis, 
BW, Germany). Secondary Electron (SE) images were 
collected at 30 kV accelerating voltage and 1.5 pA beam 
current. An electron flood gun was utilized to neutralize 
positive charges accumulated on the sample surfaces, 
which enables direct imaging of insulating materials. 
Stability of aqueous CoQ10 dispersions: Aqueous 
dispersions of the hydrophobic bioactive CoQ10 were 
prepared by dissolving either a commercial CoQ10-γ-
cyclodextrin (CoQ10-CD) complex (CAVAMAX®, 
containing 20% w/w of CoQ10) or the CoQ10-iBG 
complex loaded with 8% w/w of CoQ10 in about 250mL 
of reverse osmosis (RO) water aiming at a CoQ10 
concentration of 0.4 mg/mL by slowly dispersing the 
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powder into pre-heated RO water at 40°C in beakers and 
mixing with a magnetic stirrer. The beakers were then 
covered with parafilm and left to cool to room 
temperature on the lab bench. The dispersions were left 
at room temperature under a dark box to prevent light 
exposure and observed up to 6 months.   
Bioavailability Study: The study design and 
experimental protocol for the intestinal bioavailability 
of CoQ10 from different formulations is shown in 
Figure 1.  
CoQ10 formulations: The bioavailability of CoQ10 
was tested using four formulations: i) 3% w/w CoQ10-
iBG (n=3) pilot test, ii) 8% w/w CoQ10-iBG (n=9), iii) 
20% w/w CoQ10-CD product (n=6) and iv) Food grade 
CoQ10 in triolein (n=6). Each formulation (i-iii) was 
prepared by dispersing the sample in deionized distilled 
water heating and mixing in a water bath at 45°C for 35 
min and cooling to room temperature (~23°C). Since the 
food grade crystalline CoQ10 is insoluble in water, it 
was prepared in triolein (1mL), which represents a 
positive control for absorption of this lipophilic nutrient. 
Each formulation of CoQ10 was administered intra-
gastrically at a dose of ≈10 mg/kg body weight based on 
CoQ10 bioavailability studies in animal and rodent 
models [Hatanaka, 2008; Barakat, 2013]. 
Intestinal bioavailability: The intestinal bioavailability 
of CoQ10 from the CoQ10-iBG complex and standard 
formulations was evaluated using surgical cannulation 
of the stomach and intestinal mesenteric lymphatic 
vessel in a rodent model, which is a direct measure of 
the absorption of lipophilic nutrients and compounds, as 
previously described [Wang, 2012]. Intestinal lymph 
was collected into tubes containing EDTA and stored at 
-80°C for HPLC analyses.
HPLC Analysis of Ubiquinones: HPLC methods were 
established by modifying previously described methods 
for CoQ9 and CoQ10 [Schulz, 2006; Tarry-Adkins, 
2016; Boitier, 1998; Mosca, 2002]. The phylloquinone 
Vitamin K was used as an internal standard and the 
quantitation of CoQ9 and CoQ10 was performed using 
commercial standards to identify and detect these 
ubiquinones in intestinal lymph samples. In brief, total 
lymph ubiquinone (CoQ9 and CoQ10) was oxidized 
with 1,4-benzoquinone, and extracted with 1-propanol 
and then analyzed by reverse-phase HPLC (Agilent 
Poroshell 120, 4.6x100 mm) with UV detection at 275 
nm. Peak areas were analyzed, and CoQ9 and CoQ10 
were quantified using vitamin K as an internal standard 
(1mg/200 mL sample). Validation of the HPLC protocol 
was based on linear calibration curves of each standard 
and 99-100% recovery of the standards; vitamin K, 
CoQ9 and CoQ10 (Thermo Fisher Scientific, DC 
chemicals, Sigma-Aldrich). 
Figure 1: Study design and experimental protocol for 
determining the bioavailability of CoQ10 formulations. 
Bioavailability and Pharmacokinetics: % Total 
absorption of CoQ10, CoQ10 area under the curve 
(CoQ10-AUC), maximum concentration (cMax) were 
determined as previously described [Barakat, 2013; 
Wang, 2012]. % Absorption was adjusted per volume of 
lymph and per hour of collection to reflect 
pharmacokinetics of lymph absorption-bioavailability 
[Wang, 2012; Barakat, 2013]. 
RESULTS 
To demonstrate the capabilities of PGX Technology, 
several biopolymers were processed into open-porous 
structures, which can be impregnated with drugs or 
bioactives and utilized as bioactive delivery systems. 
Some examples are illustrated in Figure 2, showing PGX 
processed corn starch, pectin, sodium alginate, and an 
alginate-pectin exfoliated composite.  
The PGX processed oat β-glucan is displayed in Figure 
3(A) illustrating the open-porous structure. The BG 
carrier was impregnated to generate the CoQ10-iBG 
complex with spherical nanocrystals of CoQ10 with an 
average size of about 92 nm (Figure 3(B)).  
The stability of CoQ10 dispersions in water at room 
temperature is illustrated in Figure 4 after about 18 hours 
(left image) and after 6 months (right image). The 
CoQ10-iBG complex dispersion remained stable for 
more than 6 months at room temperature. 
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Figure 2: HiM images of (A) PGX processed corn 
starch, (B) pectin, (C) sodium alginate, and (D) alginate-
pectin nano-composite. Scale bar length: 200 nm. 
Figure 3: HiM images of (A) open-porous polymer 
carrier generated by PGX Technology from oat β-
glucan, and (B) CoQ10-iBG complex with nanocrystals 
of CoQ10 inside red circle (source: [Liu 2018]). Scale 
bar length: 500 nm. 
Figure 4: Stability of CoQ10 dispersions in water, 
majority of commercial CoQ10-CD (left beaker) 
precipitated in 18.35 hrs (left image), whereas the 
CoQ10-iBG complex (right beaker) was stable for more 
than 6 months (right image). 
Bioavailability of CoQ10 formulations: The results of 
the bioavailability study are shown in Table 1.  
Table 1: CoQ10 bioavailability results for the different 









% Total Abs. 2.43 ±1.01 1.71 ±0.93 4.06 ±2.12 3.27 ±2.06 
cMax (mg/ml) 53.10 ±6.23 27.54 ±7.21 63.82 ±31.04 56.97 ±24.38 
CoQ10-AUC  
(mg/ml) 
67.23 ±35.42 55.63 ±33.53  136.90 ±73.32 133.3 ±65.82 
Figure 5: Absorption kinetics of CoQ10 formulations. 
DISCUSSION 
The CoQ10 area under curve (CoQ10-AUC) was >50% 
higher for both the 8% CoQ10-iBG and 20% CoQ10-
CD formulations compared to the 3% CoQ10-iBG and 
Food CoQ10 in triolein formulations (Table 1).  The data 
show that both BG and cyclodextrin formulations 
increase the absorption of the lipophilic nutrient CoQ10; 
however, the kinetic profile was different with the 8% 
CoQ10-iBG formulation having a delayed maximal 
absorption compared to the 20% CoQ10-CD (Figure 5). 
This may reflect overall faster digestion, including 
gastric emptying of the 20% CoQ10-CD compared to 
the 8% CoQ10-iBG formulation most likely due to the 
higher viscosity of the β-glucan. Due to the fine particles 
of CoQ10 deposited on the BG carrier the bioavailability 
could be enhanced as well, which would agree with a 
previous study where CoQ10 nanocrystals with 80 nm 
diameter had a 7.3-fold increased bioavailability 
compared to a coarse suspension of the bulk drug [Sun, 
2012]. 
CONCLUSIONS 
This work demonstrates the capabilities of PGX 
Technology to generate tailor-made and tunable 
bioactive carrier/delivery systems from water-soluble 
biopolymers. Such biopolymers can be impregnated 
with lipophilic bioactives utilizing SCCO2 assisted 
adsorptive precipitation forming novel iPX 
formulations. Resulting iPX are water dispersible and 
form stable nanodispersions, which, in the case of 
CoQ10, were shown to be more bioavailable. Use of 
other polymers, polymer combinations, and cross-linked 
polymers can lead to improved delivery and release 
profiles of drugs/bioactives, which is our ongoing 
investigation. 
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ABSTRACT 
Solid dispersions have already been described over more 
than 50 years ago in scientific literature to improve 
solubility of poorly water soluble drugs. With the 
increasing number of new poorly soluble drug 
candidates discovered at early industrial stages, the 
knowledge about these metastable amorphous systems 
has significantly improved over the decades. While in 
the early days of solid dispersions pharmaceutical 
companies were rather very reluctant to invest in 
corresponding manufacturing technologies, nowadays a 
significant number of market drug products has been 
developed based upon this not novel drug delivery 
principle. The presentation will give an overview about 
properties of solid dispersions, industrial screening and 
manufacturing methods and the biopharmaceutical 
implications. 
Keywords: Solid dispersion, amorphous, solubility, 
metastable, drug delivery 
INTRODUCTION 
With the dramatic increase in poorly soluble drug 
candidates (Biopharmaceutical Classes I and IV) from 
drug discovery organisations in industrial drug 
development, scientists had to look for innovative 
approaches to improve their aqueous and in-vivo 
solubilities. Beside salt formation, particle size 
reduction (e.g. milling, micro- or nano-nizing), 
formation of Cyclodextrin complexes or incorporation 
of poorly soluble drug candidates in microemulsion 
systems (SEDDS, SMEDDS), the destruction of the 
crystal lattice in a suitable matrix and thus formation of 
a metastable amorphous system or solid dispersion has 
in the meantime turned out to become one of the most 
attractive approaches in industrial drug development.  
RESEARCH CONCEPT 
Delivery principle 
The interest in solid dispersions has started in the 1960s 
already and a first definition was given by Chiou and 
Riegelmann: “ A solid dispersion is a dispersion of one 
or more active ingredients in an inert carrier or matrix 
by the melting (fusion), solvent, or the melting-solvent 
method [Chiou, Riegelmann, 1971]. With regards to the 
metastable nature of these ideally amorphous systems, 
the question that researchers had to solve was always the 
physical stability, preventing recrystallization of try at 
least to delay such an event until the end of the shelf-life 
of a marketed drug product. Such a stabilization could 
be a solubility, thermodynamically based concept or the 
formation of a solid dispersion where the dispersed 
molecules of the poorly soluble drug candidates are 
kinetically immobilized, e.g. by adjusting high glass 
transition temperatures for the solid dispersion using the 
principles described by the Gordon-Taylor equation 
with w1 and w2 representing the weight fractions e.g. of 
drug and matrix/polymer and Tg1 and Tg2 their 
corresponding glass transition temperatures (Tg is then 
the glass transition temperature of the solid dispersion). 
Gordon-Taylor equation 
 Equation 1 
Nowadays solid dispersions are divided into 3  different 
categories or generations – starting in the early daysof 
the 1st generation with crystalline carriers (e.g. Urea, 
Fructose), moving later to polymeric carrier based (2nd 
generation) and then more recently to those of the 3rd 
generation including surface active carrier types. 
Screening approaches 
Details about different types of amorphous systems will 
be discussed during the presentation and screening 
concepts discussed (e.g. solubility in liquids, use of 
Hansen solubility parameters, DSC technique, other 
methods). Supportive modern analytical technologies 
will be briefly mentioned (e.g. SEM, TEM; micro 
Raman technique [Karavas, Georgarakis, Docoslis, 
Bikiaris, 2007]., solid stage NMR 
https://doi.org/10.24355/dbbs.084-202001220921-0
Symposium on Pharmaceutical Engineering Research SPhERe, 25 – 27 September 2019, Braunschweig/Germany 2 
Manufacturing technologies 
Over the past decades a couple of different 
manufacturing technologies have been applied. 
Generally the most prominent approaches are either 
based upon melting (e.g. hot melt-extrusion HME) or 
solvent based (e.g. spray drying, spray granulation). 
During the presentation further technical details and a 
scale-up experiment will be discussed.. 
Biophamaceutical aspects 
An increase in aqueous solubility by forming a solid 
dispersion can improve drug absorption and thus the 
bioavailability of a poorly soluble drug significantly. 
Nevertheless it needs to be considered that vertain drugs 
have a high tendency to crush out or precipitate once the 
solid dispersion reaches the gastrointestinal tract. 
Therefore formulation scientists need to test solid 
dispersion prototype formulations also with regards to 
their precipitation robustness. Addition of surfactant-
type carriers might improve the robustness significantly. 
Also such aspects have to be routinely screened 
nowadays, 
RESULTS 
The examples provided during the presentation will 
demonstrate how to develop solid dispersions by 
screening the right formulations and selecting the right 
manufacturing technology at an industrial scale 
including scaling-up and  
DISCUSSION 
The presentation explains the evolution of solid 
dispersion formuations over the last 50 years and how it 
is possible nowadays to develop stable and better up-
scalable solid dispersions than ever before. 
CONCLUSIONS 
Solid dispersions are an attractive modern approach to 
deliver poorly soluble (“brickstone”) drugs successfully 
in an industrial environment. This has led to the market 
introduction of multiple products helping to 
significantly improve patients` lives. 
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NOMENCLATURE 
SEDDS      self-emulsifying drug delivery system 
SMEDDS  self-microemulsifying drug delivery system 
SEM          scanning electron microscopy 
TEM    transmission electron microscopy 
Tg        glass transition temperature 
W1, w2      weight fraction 
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